Available online www.worldscientificnews.com

World Scientific News

An International Scientific Journal

WSN 219 (2026) 83-122 EISSN 2392-2192

The Chemist's Lens of Sickle Cell Disease: Molecular Mechanisms, Biophysical Dynamics, Tissue Pathology, and Emerging Chemical Therapeutics — A Critical Review

Kanayo Samuel Okonji[1,2]*, Alaba Olanrewaju Daramola[3], Olufemi Ebenezer Folaranmi[3], Olugbenga Tosin Alade[4]

[1]Department of Chemistry, Federal University Oye-Ekiti, Ekiti State, Nigeria.

[2]Department of Health Sciences, University of the People, Pasadena, CA, USA

[3]Department of Haematology and Blood Transfusion, Ekiti State University, Ado-Ekiti, Ekiti State, Nigeria.

[4]Department of Anatomic Pathology, Ekiti State University Teaching Hospital, Ado-Ekiti, Ekiti State, Nigeria.

*Corresponding Author: kanayosamuelokonji63@gmail.com

https://doi.org/10.65770/FPYD6165

ABSTRACT

Sickle Cell Disease (SCD) is a monogenic hemoglobinopathy arising from a single point mutation in the β-globin gene (Glu6Val), which replaces a polar glutamic acid residue with a hydrophobic valine in the β-chain of hemoglobin. Although structurally subtle, this substitution fundamentally alters intermolecular interactions within deoxygenated hemoglobin, promoting hydrophobic association, nucleation, and polymerization of hemoglobin S (HbS). The resulting supramolecular fiber formation drives erythrocyte deformation, membrane fragility, hemolysis, vaso-occlusion, and progressive tissue and organ injury.

From a chemical standpoint, SCD represents a paradigmatic example of how atomic-scale perturbations propagate across hierarchical levels, from molecular structure and intermolecular interactions to cellular dysfunction, tissue injury, and systemic disease. In this review, we synthesize evidence from more than 160 peer-reviewed studies to examine the chemistry of HbS polymerization, intermolecular thermodynamics, reaction kinetics, redox imbalance, membrane oxidative damage, and the biophysical determinants of sickling. Particular emphasis is placed on the physical chemistry governing nucleation dynamics, allosteric modulation of oxygen affinity, and reactive oxygen species (ROS) generation within sickled erythrocytes.

(Received 10 July 2026; Accepted 20 August 2026; Date of Publication 22 September 2026)

The review further connects these molecular and cellular processes with the pathological consequences observed at the tissue and organ levels, including microvascular injury, ischemia–reperfusion damage, chronic inflammation, fibrosis, and characteristic structural alterations in organs affected by SCD. This pathology-centered perspective provides a bridge between molecular mechanisms and the morphological manifestations of chronic sickle cell injury. We also evaluate emerging chemical therapeutics, including allosteric hemoglobin modifiers, antisickling agents, redox modulators, and fetal hemoglobin inducers, through the lens of structure–activity relationships and mechanistic biochemistry.

Analytical and computational approaches, including spectroscopy, crystallography, molecular docking, molecular dynamics simulations, and histopathological assessment, are discussed as complementary platforms for linking molecular events with cellular and tissue-level phenotypes and for guiding rational therapeutic development. By integrating molecular chemistry, biophysical dynamics, tissue pathology, and translational pharmacology, this review provides a chemist-centered framework that reframes SCD not merely as a genetic disorder, but as a disorder in which altered molecular interactions propagate through cellular, tissue, and organ systems to produce pathological remodeling, thereby highlighting new avenues for chemically informed therapeutic innovation.

Keywords: Hemoglobin S, Sickle Cell Disease, Polymerization, Hydroxyurea, Voxelotor, ROS, Chemical Therapeutics, Molecular Dynamics

1. INTRODUCTION

Sickle Cell Disease (SCD) is among the most prevalent and clinically consequential monogenic disorders worldwide, affecting millions of individuals across sub-Saharan Africa, the Middle East, India, Europe, and the Americas [1–5]. Despite its genetic simplicity, SCD exemplifies how a single nucleotide substitution can initiate a cascade of multiscale molecular and biophysical events culminating in systemic pathology. The disease arises from a point mutation in the *HBB* gene (β6 Glu→Val), which replaces a negatively charged, hydrophilic glutamic acid residue with a nonpolar valine at the sixth position of the β-globin chain. This seemingly modest alteration fundamentally reshapes the intermolecular interaction landscape of hemoglobin.

At the molecular level, the Glu6Val substitution introduces a hydrophobic patch on the surface of hemoglobin S (HbS), enabling aberrant intermolecular contacts under deoxygenated conditions [6–8]. In the deoxy state, conformational exposure of complementary hydrophobic pockets permits lateral and axial aggregation of HbS tetramers, initiating nucleation-dependent polymerization. The resulting supramolecular fibers distort erythrocytes into the characteristic sickled morphology [9,10]. However, the pathological consequences extend far beyond mechanical deformation.

HbS polymerization perturbs intracellular thermodynamics, redox balance, and membrane integrity. Repeated cycles of deoxygenation and reoxygenation promote oxidative stress through enhanced autoxidation of hemoglobin, generation of reactive oxygen species (ROS), and release of free heme and iron [11,12]. These redox-active species trigger lipid peroxidation, protein oxidation, and cytoskeletal destabilization, further compromising erythrocyte deformability and survival. In parallel, altered rheological properties increase blood viscosity and promote vaso-occlusion, ischemia–reperfusion injury, and chronic inflammation. Thus, SCD represents not merely a structural protein disorder, but a chemically driven network of hydrophobic interactions, kinetic phase transitions, and redox-mediated damage.

From a chemist's perspective, SCD is a paradigmatic disorder of molecular interactions and pathological self-assembly. It provides a rare opportunity to trace disease progression directly from atomic substitution to supramolecular polymer formation and ultimately to organ-level dysfunction. The physical chemistry of nucleation kinetics, intermolecular thermodynamics, and allosteric regulation of oxygen binding are central to understanding disease severity and variability [13]. Furthermore, chemical perturbations of these processes form the basis of rational therapeutic intervention.

Therapeutic strategies in SCD increasingly reflect chemical principles. Small molecules may (I) inhibit HbS polymerization by disrupting hydrophobic contacts, (II) stabilize the oxygenated (R) state of hemoglobin through allosteric modulation, (III) induce fetal hemoglobin (HbF) expression to dilute HbS polymer content, or (IV) mitigate oxidative stress via redox-active or antioxidant mechanisms [14,15]. Understanding structure–activity relationships, binding energetics, and reaction pathways is therefore essential for advancing drug discovery in this field.

In addition, analytical and computational chemistry have become indispensable tools in SCD research. Spectroscopic techniques, X-ray crystallography, mass spectrometry, and microfluidic rheological platforms elucidate structural transitions and polymer dynamics, while molecular docking and molecular dynamics simulations enable atomistic interrogation of ligand–HbS interactions and fiber stability. These approaches bridge experimental observation and theoretical modeling, providing a chemically rigorous foundation for translational innovation.

This review synthesizes evidence from over 160 peer-reviewed studies to examine SCD through a unified chemical framework. Specifically, we address:

- The molecular chemistry of HbS and the structural determinants of polymerization.
- The thermodynamics and kinetics of nucleation and fiber growth.
- Redox chemistry and oxidative stress pathways in sickled erythrocytes.
- Mechanistic analysis of emerging chemical therapeutics.
- Analytical and computational methodologies advancing mechanistic insight.

By reframing SCD as a disorder of molecular recognition, supramolecular assembly, and redox instability, this review aims to consolidate current knowledge while highlighting chemically informed avenues for therapeutic development.

2. MOLECULAR CHEMISTRY OF HEMOGLOBIN S

Hemoglobin S (HbS) differs from normal adult hemoglobin (HbA) by a single amino acid substitution at the sixth position of the β-globin chain (β6 Glu→Val) [16]. Although this mutation involves only one residue within the $\alpha_2\beta_2$ tetrameric structure of hemoglobin, it produces profound physicochemical consequences that redefine the intermolecular behavior of the protein.

Glutamic acid (Glu6) is a polar, negatively charged amino acid at physiological pH, contributing to surface electrostatic balance and aqueous solubility of hemoglobin [17]. In contrast, valine (Val6) is nonpolar and hydrophobic. The substitution therefore eliminates a surface negative charge and introduces a hydrophobic moiety that perturbs local solvent interactions and intermolecular stability.

Chemical structures of the key residues:

a) **Glutamic acid (Glu6):**

$$HOOC\text{-}CH(NH_2)\text{-}CH_2\text{-}CH_2\text{-}COOH$$

b) **Valine (Val6):**

$$\begin{array}{c} CH3 \\ | \\ CH_3\text{-}C\text{-}CH(NH_2)\text{-}COOH \end{array}$$

The chemical distinction between these residues is structurally decisive. The carboxylate-containing side chain of glutamic acid engages in hydrogen bonding and electrostatic interactions with surrounding water molecules, stabilizing hemoglobin in solution [18]. Replacement with the branched aliphatic side chain of valine removes these stabilizing interactions and generates a localized hydrophobic patch on the β-globin surface.

This alteration becomes pathologically significant during the conformational transition from the oxygenated (R) state to the deoxygenated (T) state of hemoglobin. In the deoxy conformation, structural rearrangements expose complementary hydrophobic pockets on adjacent β-chains. The Val6 residue of one HbS tetramer inserts into a hydrophobic cleft on a neighboring tetramer, forming the primary intermolecular contact that initiates aggregation [19].

The driving force behind this association is predominantly the hydrophobic effect, whereby association of nonpolar surfaces releases structured water molecules into bulk solvent, increasing system entropy and stabilizing the aggregated state. Van der Waals interactions and reduced electrostatic repulsion further reinforce tetramer–tetramer contacts. Collectively, these forces convert hemoglobin from a highly soluble oxygen carrier into a protein capable of reversible pathological self-assembly.

Polymerization proceeds via a nucleation-dependent mechanism characterized by a concentration-sensitive lag phase followed by rapid fiber elongation. The kinetics of this process are strongly influenced by oxygen tension, hemoglobin concentration, pH, temperature, and intracellular ionic strength [20]. Once nucleated, HbS molecules assemble into double-stranded helical fibers that organize into higher-order bundles within the erythrocyte cytoplasm.

At the supramolecular level, these semi-crystalline fibers distort erythrocyte morphology, reduce membrane flexibility, and impair cellular deformability. Although polymerization is reversible upon reoxygenation, repeated cycles of assembly and disassembly induce cumulative membrane stress, oxidative instability, and irreversible sickling.

Thus, the molecular chemistry of HbS illustrates a central principle in chemical biology: a single atomic substitution can reconfigure intermolecular interaction networks, alter thermodynamic stability, and transform a soluble globular protein into a self-assembling polymer system with systemic pathological consequences.

2.1. Polymerization Mechanism of HbS

HbS polymerization is a highly ordered, multistep biochemical process that converts soluble deoxygenated hemoglobin into supramolecular fibers, driving red blood cell deformation. The process follows a classical nucleation–elongation model characterized by a concentration-dependent lag phase followed by rapid fiber growth. Cooperative intermolecular interactions, primarily hydrophobic contacts introduced by the β6 Glu→Val substitution, are central to the mechanism [21,22].

Nucleation

The initial step involves the formation of a critical oligomeric nucleus composed of deoxygenated HbS tetramers:

$$n\ce{ce} \xrightarrow{} HbS_{deoxy} \overset{kn}{} ce(HbS)_n\ (nucleus)$$

Nucleation is the rate-limiting phase of polymerization. The formation of a critical nucleus is energetically unfavorable because it requires precise alignment of multiple HbS molecules. Factors such as intracellular HbS concentration, oxygen tension, temperature, pH, ionic strength, and the presence of allosteric effectors modulate the lag phase duration [23]. This explains why polymerization kinetics vary among patients and under different physiological conditions.

Elongation

After nucleation, fibers elongate rapidly through sequential addition of deoxygenated HbS monomers:

$$(HbS)_n + HbS_{deoxy} \rightarrow (HbS)_{n+1}\ (fiber)$$

This phase is dominated by hydrophobic interactions between Val6 residues and complementary hydrophobic pockets on adjacent β-globin chains:

Val6–CH_3 --- Hydrophobic Interaction --- Val6–CH_3

Elongation is further stabilized by van der Waals interactions and hydrogen bonding networks, which maintain the double-stranded helical structure of HbS fibers [24]. During elongation, fibers align longitudinally and laterally within the erythrocyte cytoplasm, progressively increasing intracellular rigidity.

Fiber Aggregation and Supramolecular Assembly

Individual fibers associate laterally to form thicker bundles, creating semi-crystalline networks that distort red blood cell morphology into the characteristic sickle shape. This higher-order aggregation amplifies mechanical rigidity, increases intracellular viscosity, and impairs microvascular flow [21,25]. Lateral association is influenced by ionic interactions, macromolecular crowding, and oxidative cross-linking of cytoskeletal proteins, which further stabilize fiber bundles and promote persistent sickling under repeated deoxygenation cycles.

➢ **Thermodynamics of Polymerization**

The spontaneity of HbS fiber formation is described by the Gibbs free energy relationship:

$$\Delta G = \Delta H - T\Delta S$$

Where:

ΔH represents favorable enthalpic contributions from hydrophobic interactions, van der Waals forces, and hydrogen bonding within the fiber lattice.

ΔS reflects the entropic cost associated with reduced conformational freedom as individual HbS tetramers become ordered within fibers.

The loss of conformational entropy is partially compensated by the entropy gain from release of structured water molecules surrounding hydrophobic surfaces, making the overall process thermodynamically favorable under deoxygenated conditions [22,23]. Fiber formation is reversible upon reoxygenation, but repeated cycles promote cumulative membrane stress, oxidative damage, and irreversible sickling [24,25].



Figure 1. Schematic of Hbs Nucleation, Fiber Elongation, and Lateral Aggregation Showing Val6 Hydrophobic Interactions.

2.2. Heme Chemistry and Redox Reactions

Each hemoglobin subunit contains a heme prosthetic group (Fe^{2+}-protoporphyrin IX), which serves as the central chemical site for oxygen binding and redox activity. In sickled erythrocytes, the Fe^{2+} ion within HbS is particularly prone to auto-oxidation, generating reactive oxygen species (ROS) and initiating oxidative stress cascades:

$$ceHbS - Fe_2^{+} + O2 \text{ –> } HbS - Fe_3^{+} + O_2^{\bullet -}$$

The mechanism involves electron transfer from the ferrous iron (Fe^{2+}) to molecular oxygen, producing superoxide anion ($O_2\bullet^-$). This process is accelerated in sickled cells due to repeated polymerization and fiber formation, which alter local protein microenvironments and increase the exposure of heme to solvent [26]. Superoxide radicals subsequently participate in secondary reactions, including the formation of hydrogen peroxide (H_2O_2) and hydroxyl radicals (•OH), further amplifying oxidative stress.

Cells rely on both enzymatic and non-enzymatic antioxidant defenses to mitigate ROS. Key enzymatic pathways include:

Superoxide dismutation (SOD-mediated):

$$ce2O_2^{\bullet -} + 2H^+ -> H_2O_2 + O_2$$

Catalase-mediated decomposition:

$$ce2H_2O_2 -> [catalase]\ 2H_2O + O_2$$

Glutathione peroxidase (GPx) reaction:

$$ce2GSH + H_2O_2 ->[GPx]GSSG + 2H_2O$$

Non-enzymatic pathways also contribute, with reduced glutathione (GSH), ascorbate, and other small-molecule antioxidants chemically scavenging ROS before they damage membranes or cytoskeletal proteins [27]. The cumulative oxidative stress contributes directly to lipid peroxidation, protein carbonylation, and hemoglobin oxidation, compromising erythrocyte deformability and promoting hemolysis.

Moreover, ROS interact with polymerized HbS fibers, further stabilizing aggregates and accelerating membrane rigidity. The combination of fiber-induced mechanical stress and oxidative damage explains the high propensity of sickled cells to undergo hemolysis and participate in vaso-occlusive events, linking chemical reactions at the molecular level to cellular and tissue-level pathology [28].

2.3. Biochemical Pathway: Hydroxyurea-Induced HbF

Hydroxyurea is a cornerstone therapeutic for SCD, acting chemically to induce fetal hemoglobin (HbF) production, which dilutes intracellular HbS and inhibits polymerization [29]. Its chemical and biochemical mechanism is multi-step:

Hydroxyurea metabolism to nitric oxide (NO):

$$ce\ H_2N - NHO - CH_2 - OH ->NO + metabolites$$

Hydroxyurea is metabolized in erythrocytes and liver cells to generate nitric oxide, a reactive gaseous molecule capable of signaling downstream transcriptional responses.

Activation of soluble guanylyl cyclase (sGC) and cGMP signaling:

$$ce\ NO -> sGC -> cGMP -> \gamma - globintranscription -> HbFsynthesis$$

NO activates sGC, increasing intracellular cyclic GMP (cGMP) levels. cGMP in turn activates protein kinases and transcription factors that upregulate γ-globin gene expression, leading to HbF synthesis. At the molecular level, HbF tetramers competitively interfere with HbS polymer contacts, reducing nucleation rates and fiber elongation [30].

Hydroxyurea's chemical action has multiple downstream effects:

- **Reduction of HbS concentration**: By increasing HbF proportion, the effective concentration of polymerizable HbS decreases.
- **Modulation of redox environment**: Hydroxyurea-derived NO can react with superoxide to form peroxynitrite, influencing ROS dynamics.
- **Improvement of erythrocyte deformability**: Chemical modulation of hemoglobin composition translates into enhanced mechanical flexibility and reduced vaso-occlusion.

Overall, hydroxyurea demonstrates how a small chemical intervention can strategically alter the biophysical behavior of hemoglobin at both molecular and cellular levels, linking therapeutic chemistry directly to disease mitigation.

3. BIOPHYSICAL DYNAMICS AND COMPUTATIONAL CHEMISTRY OF HEMOGLOBIN S

3.1. Fiber Formation and Mechanical Properties

The polymerization of deoxygenated HbS results in the assembly of long, semi-crystalline fibers that mechanically deform red blood cells into the characteristic sickle shape. At the molecular level, the stability and growth of these fibers are governed by a combination of chemical interactions and structural constraints:

- **Hydrophobic interactions:** Val6 residues on adjacent β-globin chains engage in specific hydrophobic contacts that nucleate and stabilize fiber assembly. These interactions drive both axial and lateral alignment of HbS tetramers and are the primary thermodynamic force favoring fiber elongation [31].
- **Hydrogen bonding:** Backbone and side-chain hydrogen bonds along β-globin chains reinforce fiber integrity, providing additional enthalpic stabilization and defining the helical double-stranded architecture of HbS polymers [32].
- **Van der Waals interactions:** Close packing along the fiber axis allows complementary side chains to engage in dispersive forces, further reducing the free energy of the polymerized state [33].

The cumulative effect of these interactions produces fibers with high mechanical rigidity. The persistence length of HbS fibers, a quantitative measure of stiffness, is directly influenced by the number and strength of hydrophobic contacts and hydrogen bonds along the polymer chain. Fibers with greater persistence length resist bending, which translates at the cellular level to reduced erythrocyte deformability and increased blood viscosity, especially under low-oxygen conditions [34].

From a biophysical perspective, the density and organization of HbS fibers within the cytoplasm alter intracellular pressure, membrane tension, and cytoskeletal dynamics. These changes explain the heterogeneous morphology observed in sickled cells and the variable propensity for vaso-occlusion in microvascular networks [32]. Computational simulations and molecular dynamics studies have further illustrated that subtle perturbations in the Val6 hydrophobic interface or hydrogen bonding network can significantly affect fiber nucleation rates, elongation kinetics, and supramolecular stability [35].



Figure 2. Schematic of Hbs Fiber Showing Val6-Mediated Hydrophobic Interface and Hydrogen Bonding Along β-Globin Chains.

3.2. Computational Insights into Polymerization

Molecular dynamics (MD) simulations and energy minimization studies have provided critical atomic-level insights into HbS polymerization, complementing experimental observations. These computational approaches allow visualization of nucleation, fiber elongation, and supramolecular assembly, as well as the energetic effects of small-molecule therapeutics [36–40].

Nucleation Dynamics

MD simulations demonstrate that deoxygenated HbS monomers spontaneously cluster to form oligomeric nuclei. Val6 hydrophobic patches on β-globin chains serve as primary nucleation sites, guiding the initial intermolecular alignment [36]. The simulations reveal that nucleation is highly sensitive to local concentration, temperature, and solvent dynamics, reflecting the experimentally observed lag phase in polymerization kinetics. Energetically, nucleation requires overcoming an initial free energy barrier, which is stabilized once a critical oligomeric nucleus forms.

Fiber Elongation

Following nucleation, fiber elongation proceeds via sequential addition of HbS monomers. Computational studies highlight:

- The stability of hydrophobic Val6–Val6 contacts, which anchor each incoming monomer.
- The formation of transient hydrogen bonds along β-globin chains, providing additional enthalpic stabilization during fiber growth [37].
- The helical twist and axial packing of fibers, which determine persistence length and mechanical rigidity.

Energy profiles from MD simulations indicate that fiber elongation is energetically downhill, making polymer growth spontaneous once nucleation occurs. Simulations also demonstrate that subtle perturbations in hydrophobic interfaces or hydrogen bonding networks can markedly alter polymer stability, providing a mechanistic rationale for the variability in disease severity.

Drug Interactions and Energy Modulation

Small molecules, including Voxelotor and hydroxyurea derivatives, modulate HbS polymerization by altering the energy landscape of the reaction [38–40]. MD studies reveal:

- Voxelotor binds at the α-chain interface, stabilizing the oxygenated R-state of hemoglobin and increasing the energetic barrier to nucleation [38].
- Hydroxyurea derivatives indirectly reduce polymerization by increasing HbF content, which disrupts hydrophobic contacts and lowers fiber growth rates [39].
- Energy minimization simulations indicate that these interventions reduce fiber elongation free energy and increase the lag phase, effectively delaying sickling at the molecular level [40].

Reaction Coordinate (Simplified Chemical Representation)

The polymerization process can be summarized chemically as:

$$ceHbS_{deoxy} -> [nucleation]\ (HbS)_n -> [elongation]\ (HbS)_{n+1}\ (fiber)$$

This schematic emphasizes key chemical steps, nucleation and elongation, and highlights molecular sites where therapeutic molecules can intervene to inhibit polymer formation.

3.3. Chemical Environment Effects

The kinetics and thermodynamics of HbS polymerization are highly sensitive to the chemical environment of the erythrocyte. Local pH, ionic strength, and the presence of allosteric effectors directly influence nucleation, fiber elongation, and higher-order aggregation, linking molecular chemistry to macroscopic cell mechanics [41].

pH Effects

Protonation states of acidic residues in hemoglobin, particularly Glu6 and surrounding residues, are pH-dependent. Under acidic conditions, protonation reduces negative charges, weakening electrostatic repulsion between HbS monomers and promoting nucleation and fiber growth. Conversely, alkaline conditions increase electrostatic repulsion, raising the nucleation energy barrier and slowing polymerization [41,42]. MD and electrostatic simulations show that even small pH shifts can alter hydrogen bonding networks along β-globin chains, affecting fiber stability and persistence length.

Ionic Strength

Cytoplasmic ionic strength modulates polymerization by screening surface charges on HbS tetramers. Elevated salt concentrations reduce electrostatic repulsion, facilitating lateral fiber association and supramolecular assembly [43]. Computational studies indicate that ionic screening promotes tighter packing of fibers, increases hydrophobic contact stabilization, and lowers the Gibbs free energy of polymerization. This explains why variations in intracellular electrolyte composition can modulate sickling severity at the molecular level.

Allosteric Modulators

Allosteric molecules such as 2,3-bisphosphoglycerate (2,3-BPG) and CO_2 influence hemoglobin's oxygen affinity, indirectly affecting polymerization. 2,3-BPG stabilizes the deoxygenated T-state, promoting HbS polymerization by favoring conformations that expose the Val6 hydrophobic patch [44]. Conversely, molecules that shift hemoglobin toward the R-state reduce nucleation probability and elongation rates. These interactions illustrate how small chemical effectors can modify both the thermodynamic landscape and the kinetic pathways of fiber formation.

Chemical Insight

Collectively, the chemical environment , pH, ionic composition, and allosteric modulators, dictates the thermodynamic favorability and kinetic accessibility of HbS polymerization. These effects demonstrate a direct link between molecular chemistry and biophysical behavior: small changes in local chemical conditions translate into measurable alterations in fiber formation, persistence length, erythrocyte rigidity, and vaso-occlusive risk [45].

3.4. Biophysical Consequences and Therapeutic Implications

The chemical and mechanical properties of HbS fibers have direct consequences at the cellular, tissue, and systemic levels, shaping the clinical manifestations of SCD. Understanding these links through a chemist's lens allows precise identification of molecular targets for therapeutic intervention [46].

Decreased Red Blood Cell Deformability

Rigid, semi-crystalline HbS fibers increase intracellular stiffness, reducing erythrocyte deformability. This mechanical impairment compromises the ability of red blood cells to traverse narrow capillaries, promoting microvascular obstruction and vaso-occlusion. Molecularly, the persistence length of fibers and the density of hydrophobic and hydrogen bonding interactions correlate with the degree of cellular rigidity [46,47].

Computational simulations further show that even partial inhibition of nucleation or elongation can significantly restore cell flexibility, emphasizing the importance of chemical modulation.

Amplification of Oxidative Stress

Dense polymer networks concentrate heme groups and exacerbate auto-oxidation reactions:

$$ce\ HbS - Fe^{2+} + O_2 -> HbS - Fe^{3+} + O2^{\bullet -}$$

Fiber aggregation increases the local concentration of reactive heme iron, accelerating superoxide and hydrogen peroxide generation. This amplified oxidative stress damages membrane lipids, cytoskeletal proteins, and hemoglobin itself, contributing to hemolysis, inflammation, and endothelial dysfunction [48]. Chemical interventions that modify HbS polymerization can indirectly reduce oxidative stress by decreasing fiber density and heme exposure.

Therapeutic Chemical Interventions

Small-molecule therapeutics exploit the molecular mechanisms of polymerization to reduce sickling:

- **Hydroxyurea:** Induces HbF production, diluting HbS and disrupting nucleation sites, which decreases fiber formation. The chemical conversion of hydroxyurea to nitric oxide and the subsequent activation of the cGMP pathway illustrate a direct molecular link between chemical modulation and biophysical outcomes [49].
- **Voxelotor:** Binds allosterically to the α-chain interface of HbS, stabilizing the oxygenated R-state, increasing the energy barrier to nucleation, and reducing polymer elongation. Computational and MD studies show that this energetic modulation translates into fewer rigid fibers and improved erythrocyte deformability [50].

These therapeutic strategies demonstrate how a chemistry-focused understanding of HbS polymerization informs drug design, allowing interventions that act at precise molecular sites to produce measurable biophysical and clinical benefits.

4. REDOX CHEMISTRY AND OXIDATIVE STRESS IN SICKLE CELLS

4.1. Auto-Oxidation of Hemoglobin S

Hemoglobin S (HbS) is inherently prone to **auto-oxidation**, a chemical process in which the ferrous iron (Fe^{2+}) at the heme center is oxidized to ferric iron (Fe^{3+}), producing reactive oxygen species (ROS) [51]. This reaction can be represented as:

$$ce\ HbS - Fe^{2+} + O_2 -> HbS - Fe^{3+} + O2^{\bullet -}$$

$Fe^{2+} \rightarrow Fe^{3+}$: Oxidation occurs at the heme iron center, facilitated by deoxygenation and polymerization of HbS fibers.

Superoxide radical ($O_2^{\bullet -}$): Highly reactive, it initiates secondary oxidative reactions, including hydrogen peroxide formation, hydroxyl radical generation, and lipid peroxidation.

The chemical mechanism involves electron transfer from Fe^{2+} to molecular oxygen, producing $O_2^{\bullet -}$. In deoxygenated HbS fibers, the local microenvironment , including dense hydrophobic packing and constrained protein dynamics , accelerates auto-oxidation by increasing the proximity of heme centers and reducing solvent-mediated quenching of ROS [52].

Auto-oxidation is the primary source of intracellular ROS in sickled erythrocytes, triggering oxidative stress cascades that damage lipids, proteins, and nucleic acids [53]. Key secondary reactions include:

Superoxide dismutation:

$$\ce 2O_2^{\bullet -} + 2H^+ -> H_2O_2 + O_2$$

Hydrogen peroxide decomposition:

$$\ce 2H_2O_2 ->[catalase] 2H_2O + O_2$$

Glutathione-mediated detoxification:

$$ce 2GSH + H_2O_2 ->[GPx] GSSG + 2H_2O$$

These chemical reactions amplify the oxidative burden in sickled cells, contributing to membrane rigidity, hemolysis, and vaso-occlusion [54,55]. Computational studies confirm that ROS generation is spatially concentrated along polymerized fiber networks, providing a mechanistic explanation for the link between HbS fiber density and oxidative damage.

4.2. Reactive Oxygen Species (ROS) Detoxification

Sickled red blood cells are exposed to high levels of ROS due to HbS auto-oxidation and fiber-associated oxidative stress. To counteract ROS, cells employ a combination of enzymatic and non-enzymatic detoxification mechanisms, which act at the chemical level to neutralize reactive species before they damage membranes, proteins, and hemoglobin itself [56].

Superoxide Dismutation (SOD-Mediated)

Superoxide radicals generated from Fe^{2+} oxidation are converted to hydrogen peroxide and molecular oxygen by superoxide dismutase (SOD):

$$\ce 2O_2^{\bullet -} + 2H^+ ->[SOD] H_2O_2 + O_2$$

The SOD-catalyzed reaction is highly efficient, lowering superoxide concentrations and preventing further radical propagation. Chemically, SOD facilitates a redox cycle in which one superoxide is reduced while the other is oxidized, regenerating the active site and enabling rapid turnover [57].

Catalase-Mediated Decomposition of Hydrogen Peroxide

Hydrogen peroxide produced by SOD is further decomposed by catalase:

$$\ce{2H2O2 ->[catalase] 2H2O + O2}$$

Catalase accelerates the disproportionation of H_2O_2 into water and oxygen, limiting the formation of highly reactive hydroxyl radicals (•OH) through Fenton chemistry. In sickled cells, the local concentration of H_2O_2 can exceed catalase capacity, leading to residual oxidative stress [58].

Glutathione Peroxidase (GPx)-Mediated Reduction

Glutathione peroxidase reduces H_2O_2 to water using reduced glutathione (GSH) as a cofactor:

$$\ce{2GSH + H2O2 ->[GPx] GSSG + 2H2O}$$

This reaction not only detoxifies H_2O_2 but also maintains redox homeostasis within the cell. The ratio of GSH to oxidized glutathione (GSSG) is a chemical indicator of oxidative stress, reflecting the balance between ROS production and detoxification capacity [59,60].

Chemical and Biophysical Implications

In SCD, excessive ROS from dense HbS polymer networks overwhelms enzymatic defenses, resulting in:

- **Lipid peroxidation**: Oxidative attack on membrane phospholipids increases rigidity.
- **Protein oxidation**: Cytoskeletal proteins and hemoglobin are chemically modified, destabilizing cellular architecture.
- **Inflammatory signaling**: ROS act as chemical signals activating endothelial and immune responses.

The failure of ROS detoxification in sickled cells illustrates how chemical kinetics, enzyme capacity, and radical reactivity converge to produce pathological outcomes, bridging molecular chemistry with clinical consequences [56–60].

4.3. Fenton Chemistry and Secondary Oxidative Stress

In sickled red blood cells, ferric (Fe^{3+}) and ferrous (Fe^{2+}) heme iron can participate in Fenton-type reactions, generating highly reactive hydroxyl radicals (•OH) that propagate oxidative damage:

$$\ce{Fe^{2+} + H2O2 -> Fe^{3+} + OH^- + •OH}$$

- **Fe^{2+} → Fe^{3+}:** The ferrous iron in heme acts as a reducing agent, transferring an electron to hydrogen peroxide.
- **Hydroxyl radical (•OH):** One of the most reactive ROS species, capable of initiating radical chain reactions that chemically attack multiple cellular targets.

➢ **Mechanistic Insights**

Fenton chemistry amplifies the oxidative burden initiated by HbS auto-oxidation. Key chemical consequences include:

- **Lipid peroxidation:** Hydroxyl radicals abstract hydrogen atoms from unsaturated fatty acids in the membrane, forming lipid radicals and peroxides, which compromise membrane integrity [61].
- **Protein oxidation:** Cytoskeletal and membrane proteins undergo carbonylation and cross-linking, altering mechanical properties and contributing to rigidity and fragility of sickled cells [62].
- **Nucleic acid damage:** Although mature red blood cells lack nuclei, oxidative stress can affect residual RNA and mitochondrial-like elements in reticulocytes, altering cellular metabolism [63].
- **Radical propagation:** Hydroxyl radicals initiate secondary radical chain reactions, generating additional ROS species such as hydroperoxyl (HO_2•) and peroxyl radicals (ROO•), further amplifying oxidative stress [64].

➢ **Chemical and Pathophysiological Implications**

Fenton-mediated ROS production links molecular-level redox chemistry to cellular pathology. Dense HbS polymer networks concentrate heme iron, enhancing local Fenton reactions and creating hotspots of oxidative stress [65]. This chemical cascade explains:

- Accelerated hemolysis in sickled cells
- Increased membrane rigidity, contributing to vaso-occlusion
- Elevated inflammatory signaling, promoting endothelial dysfunction

By understanding these reactions from a chemist's perspective, therapeutic strategies can be designed to scavenge ROS, chelate iron, or stabilize hemoglobin, directly mitigating secondary oxidative stress and its biophysical consequences.

4.4. Chemical Consequences for Red Blood Cells

The cumulative oxidative stress in sickled red blood cells, driven by HbS auto-oxidation, Fenton chemistry, and ROS propagation, produces direct chemical damage to cellular components, which translates into major pathophysiological outcomes:

Membrane Lipid Peroxidation

Hydroxyl radicals (•OH) and other ROS attack polyunsaturated fatty acids in the lipid bilayer, initiating radical chain reactions:

- Hydrogen abstraction from lipid chains generates lipid radicals, which react with oxygen to form lipid peroxides.
- Lipid peroxidation reduces membrane fluidity and disrupts ion gradients, directly impacting red blood cell deformability [66,67].

Hemolysis due to Cytoskeletal Weakening

ROS chemically modify cytoskeletal proteins (e.g., spectrin, actin, and ankyrin) through carbonylation, crosslinking, and thiol oxidation:

- These chemical alterations compromise the mechanical integrity of the red blood cell membrane.
- Increased fragility leads to hemolysis, releasing free hemoglobin and iron, which further fuels ROS generation via Fenton reactions [67,68].

Activation of Inflammatory Pathways

ROS act as chemical signals, activating intracellular and endothelial pathways:

- Oxidative modification of red blood cell surface proteins triggers adhesion to endothelial cells.
- Secondary radical species and peroxidized lipids amplify pro-inflammatory signaling, recruiting leukocytes and promoting vascular inflammation [69].

Promotion of Vaso-Occlusive Crises

Chemical damage to both red blood cell membranes and the endothelium increases cell rigidity and adhesion, creating blockages in the microvasculature:

- HbS polymer density, oxidative modifications, and Fenton-mediated radical hotspots all converge to enhance vaso-occlusive potential.
- From a chemistry perspective, the interplay of hydrophobic interactions, redox reactions, and radical chemistry directly determines these pathophysiological outcomes [70].

➢ **Chemical Insight for Therapeutic Targeting**

Understanding these chemical consequences allows identification of rational therapeutic targets:

- Antioxidants and ROS scavengers can neutralize radicals before they propagate damage.
- Iron chelators reduce Fenton-mediated hydroxyl radical formation.
- Small molecules stabilizing HbS in the oxygenated state reduce polymer formation and limit radical concentration.

By integrating chemical, biophysical, and computational perspectives, interventions can be mechanistically designed to mitigate both molecular damage and clinical manifestations [69,70].

The cumulative effect of ROS and redox reactions in sickled cells includes:

- Membrane lipid peroxidation
- Hemolysis due to weakened cytoskeleton
- Activation of inflammatory pathways
- Promotion of vaso-occlusive crises via endothelial damage

From a chemistry perspective, these events highlight the direct link between molecular redox reactions and physiological outcomes, providing rational targets for therapeutic intervention [66–70].

4.5. Therapeutic Modulation of Redox Chemistry

Targeting oxidative stress in sickled red blood cells relies on chemical and pharmacological interventions that modulate ROS generation, propagation, and detoxification. These strategies act at the molecular level to reduce cellular damage and downstream clinical complications [71].

L-Glutamine Supplementation

L-Glutamine provides substrates for NADPH generation, which replenishes reduced glutathione (GSH), a primary cellular antioxidant:

$$ce2GSH+H_2O_2->[GPx]GSSG+2H_2O$$

Increased GSH levels enhance detoxification of hydrogen peroxide via glutathione peroxidase, limiting hydroxyl radical formation.

By chemically sustaining the redox buffer, L-glutamine reduces lipid peroxidation, protein oxidation, and hemolysis [71,72].

Hydroxyurea

Hydroxyurea indirectly mitigates oxidative stress through chemical modulation of HbS polymerization:

- Induces fetal hemoglobin (HbF), diluting HbS concentration and decreasing polymer nucleation and elongation.
- Reduced polymer density lowers hemolysis and free iron availability, limiting Fenton-mediated hydroxyl radical formation.
- Hydroxyurea metabolism to nitric oxide (NO) also contributes to vasodilation and improved oxygenation, further stabilizing HbS [73].

Antioxidant Small Molecules

Small-molecule antioxidants are designed to directly scavenge ROS or inhibit radical propagation:

- **Fenton chemistry inhibitors:** Chelators such as deferoxamine bind Fe^{2+}, preventing hydroxyl radical generation.
- **Direct ROS scavengers:** Molecules like N-acetylcysteine neutralize superoxide and peroxides, interrupting radical chain reactions.
- Computational modeling allows rational design of these compounds to target specific ROS pathways and minimize off-target effects [74,75].

Figure 3 summarizes the reaction network of redox chemistry in sickled cells, including:

- HbS auto-oxidation producing superoxide ($O_2^{\bullet -}$)
- Superoxide dismutation to hydrogen peroxide (H_2O_2)
- Catalase and GPx-mediated detoxification
- Hydroxyl radical formation via Fenton chemistry

This schematic highlights the molecular sites where therapeutics can intervene, providing a chemically guided framework for SCD management.



Figure 3. Reaction Schematic Showing ROS Generation From HbS Auto-Oxidation, Superoxide Dismutation, Hydrogen Peroxide Decomposition, and Hydroxyl Radical Formation via Fenton Reaction.

5. CHEMICAL THERAPEUTICS IN SICKLE CELL DISEASE

5.1. Hydroxyurea: Induction of Fetal Hemoglobin

Hydroxyurea (HU, $H_2N–NHO–CH_2–OH$) is the most widely used pharmacological agent in SCD, with effects that are fundamentally chemical and mechanistic in nature. Its therapeutic action combines direct molecular modulation with indirect biophysical outcomes, providing a chemist-centric framework for understanding SCD treatment [76].

Metabolism to Nitric Oxide (NO)

Hydroxyurea undergoes metabolic transformation in erythrocytes and the liver to generate nitric oxide (NO) and other metabolites:

$$ceH_2N - NHO - CH_2 - OH -> [metabolism]\ NO + metabolites$$

- NO acts as a diffusible signaling molecule, capable of chemical interactions with heme iron and thiol groups.
- These chemical interactions initiate downstream signaling cascades that are critical for HbF induction [76,77].

Activation of cGMP Signaling and γ-Globin Transcription

Nitric oxide activates soluble guanylyl cyclase (sGC), increasing cyclic GMP (cGMP) levels:

$$ceNO -> sGC -> cGMP -> \gamma - globintranscription ->HbFsynthesis$$

- Increased cGMP levels chemically modulate transcription factors involved in γ-globin gene activation.
- HbF ($\alpha_2\gamma_2$) produced through this pathway lacks the Val6 substitution found in HbS, thereby diluting HbS concentration and disrupting polymer nucleation and elongation.
- The chemical consequence is a reduction in HbS fiber formation, directly connecting molecular modulation to improved red blood cell deformability [78].

Oxidative Feedback Mechanism

Hydroxyurea also exerts mild oxidative effects:

- Low-level ROS generation induced by HU serves as a stress signal, enhancing γ-globin transcription through redox-sensitive pathways.
- This paradoxical effect illustrates a chemically mediated feedback loop, where controlled oxidative stress contributes to therapeutic benefit.
- Mechanistically, HU-induced ROS may transiently modify transcription factors or signaling proteins, providing a molecular trigger for HbF synthesis [79,80].

Figure 4 depicts:

- Hydroxyurea structure ($H_2N–NHO–CH_2–OH$)
- Metabolic conversion to NO
- Activation of cGMP signaling
- γ-Globin transcription leading to HbF induction
- Feedback loop via mild ROS generation

This schematic emphasizes the chemical mechanisms underlying HU therapy, highlighting sites where molecular interventions translate into measurable biophysical and clinical improvements.



Figure 4. Hydroxyurea Structure and Pathway to Hbf Induction.

5.2. Voxelotor: Allosteric Stabilization of HbS

Voxelotor (GBT440) is a small-molecule therapeutic that binds specifically to the α-chain of hemoglobin S, chemically stabilizing the oxygenated R-state and directly preventing HbS polymerization [81]. Its mechanism exemplifies how rational small-molecule design can modulate protein allostery at the chemical level.

Covalent and Non-Covalent Binding

Voxelotor forms a reversible covalent bond with the N-terminal valine of the α-chain:

$$ceHbS_{deoxy} + Voxelotor -> [binding] HbS_{oxy} - Voxelotor$$

This chemical interaction shifts the equilibrium toward the oxygenated (R) state, increasing the fraction of oxy-HbS in circulation. By stabilizing oxy-HbS, Voxelotor reduces the concentration of deoxy-HbS, which is the species responsible for Val6-mediated hydrophobic interactions and fiber nucleation. Non-covalent contacts, including hydrogen bonding and van der Waals interactions, further enhance binding specificity and stability [81,82].

Allosteric Modulation and Polymerization Kinetics

The chemical consequence of Voxelotor binding is allosteric stabilization:

Oxy-HbS has reduced tendency to participate in intermolecular hydrophobic interactions that nucleate polymer fibers.

By modifying the energy landscape of hemoglobin conformations, Voxelotor slows nucleation and elongation kinetics of HbS fibers, providing a thermodynamically favorable shift that reduces sickling [83,84].

Computational and biophysical studies support that Voxelotor-bound HbS maintains oxygenation at lower pO_2, further preventing polymer formation.

Figure 5 illustrates:

- The chemical structure of Voxelotor
- Binding site on the HbS α-chain
- Stabilization of the oxygenated R-state
- Inhibition of Val6-mediated fiber polymerization

Therapeutic Implications

From a chemical perspective, Voxelotor demonstrates targeted modulation of protein chemistry to achieve a clinical effect. Its mechanism highlights the importance of small-molecule design in controlling allosteric equilibria and polymerization kinetics, bridging molecular chemistry and biophysical outcomes in SCD [84,85].



Figure 5. Chemical Structure of Voxelotor and Schematic of Binding to HbS α-Chain.

Voxelotor represents a direct chemical modulation of protein allostery, illu strating the power of small-molecule design in controlling polymerization kinetics [85].

5.3. L-Glutamine: Modulation of Redox Chemistry

L-Glutamine ($C_5H_{10}N_2O_3$) supplementation in SCD targets the oxidative stress pathways, acting at the chemical level to maintain redox homeostasis and limit ROS-mediated damage. Its mechanism can be understood through molecular and biochemical chemistry [86].

Substrate for NADPH Production

Glutamine enters erythrocytes and undergoes metabolic conversion:

$$ceGlutamine->Glutamate->\alpha-Ketoglutarate->NADPHgeneration$$

Through this pathway, glutamine provides reducing equivalents (NADPH) essential for maintaining the intracellular redox balance. NADPH is a key cofactor for glutathione reductase, linking chemical metabolism directly to ROS detoxification [86].

In SCD, where ROS production is elevated due to HbS auto-oxidation and Fenton chemistry, glutamine supplementation chemically enhances the cell's ability to neutralize radicals [86,87].

Maintenance of Reduced Glutathione (GSH)

NADPH maintains GSH in its reduced form, enabling detoxification of hydrogen peroxide and other reactive species:

$$ceGSSG + NADPH + H^{+}->2GSH + NADP+$$

This reaction, catalyzed by glutathione reductase, ensures a steady supply of GSH, the primary intracellular antioxidant.

Chemically, GSH reacts with hydrogen peroxide and lipid peroxides, converting them to harmless water and alcohols, interrupting radical propagation [88,89].

Chemical and Physiological Implications

By enhancing intracellular antioxidant capacity, L-glutamine:

- Reduces oxidative damage to membrane lipids and cytoskeletal proteins
- Limits hemolysis, decreasing free iron that would otherwise fuel Fenton reactions
- Supports endothelial integrity and vascular function, indirectly mitigating vaso-occlusive crises

From a chemist's perspective, L-glutamine acts as a molecular redox buffer, linking metabolic chemistry to cellular protection in SCD [90].

5.4. Emerging Chemical Therapeutics

Recent advances in SCD therapy have focused on chemically precise interventions that target the molecular and biophysical drivers of HbS polymerization, oxidative stress, and red blood cell pathology. These emerging therapeutics illustrate how rational chemical design can modulate SCD at the molecular level [91].

Allosteric Modulators

Small molecules targeting allosteric sites, particularly the 2,3-bisphosphoglycerate (2,3-BPG) binding pocket on hemoglobin, are under investigation:

- By chemically modifying the HbS oxygen-binding equilibrium, these modulators increase oxygen affinity, reducing deoxy-HbS concentration.
- Stabilization of the R-state decreases the probability of Val6-mediated hydrophobic interactions, thereby inhibiting polymer nucleation.
- Mechanistically, allosteric modulation represents a chemical lever to shift conformational equilibria without altering the primary protein sequence [91–93].

HbS Polymerization Inhibitors

Direct small-molecule inhibitors of HbS polymerization are being designed to occupy hydrophobic pockets critical for Val6 interactions:

- These molecules physically block the nucleation interface, preventing lateral association of fibers.
- Structure-activity relationship (SAR) studies guide optimization of hydrophobic complementarity, enhancing binding specificity and polymerization inhibition.
- Computational chemistry and molecular docking are key tools to predict binding affinity and orientation, accelerating rational design [94–97].

Antioxidants and Enzyme Mimetics

Synthetic compounds mimicking superoxide dismutase (SOD) or catalase activity provide targeted chemical modulation of oxidative stress:

- Enzyme mimetics catalytically neutralize ROS, interrupting radical chain reactions initiated by HbS auto-oxidation and Fenton chemistry.
- Some antioxidants are designed with dual functionality, both scavenging radicals and chelating free iron to prevent hydroxyl radical formation.
- Chemical optimization aims to maximize radical quenching efficiency while minimizing off-target redox reactions [98–100].

Chemical Insight and Therapeutic Rationale

These emerging strategies demonstrate that precise molecular interventions can:

- Modulate HbS polymerization kinetics
- Stabilize hemoglobin conformational states
- Mitigate oxidative stress at its chemical source
- Reduce downstream biophysical and clinical consequences, such as hemolysis and vaso-occlusion

From a chemist's perspective, the integration of structure-based drug design, computational modeling, and mechanistic chemistry provides a rational path toward next-generation SCD therapeutics.

6. ANALYTICAL AND COMPUTATIONAL CHEMISTRY APPROACHES IN SICKLE CELL DISEASE

6.1. Spectroscopic and Structural Analysis

A detailed understanding of HbS polymerization, oxidative stress, and drug interactions depends on chemical and structural analysis techniques. These methods provide atomic- and molecular-level insights, essential for rational therapeutic design [101].

UV-Visible (UV-Vis) Spectroscopy

HbS heme groups absorb light in the Soret region (~414 nm for oxy-Hb), allowing monitoring of heme oxidation states.

Deoxygenation or polymerization shifts the absorbance profile, reflecting changes in $Fe^{2+} \leftrightarrow Fe^{3+}$ ratios and fiber formation:

$$ceHbS{-}Fe2{+}{<}{=}{>}HbS{-}Fe^{3+}{+}e^{-}$$

Drug binding (e.g., Voxelotor, hydroxyurea) can also produce characteristic spectral shifts, providing direct chemical evidence of allosteric modulation or covalent interaction [101–103].

Circular Dichroism (CD) Spectroscopy

CD spectroscopy monitors secondary structure changes in hemoglobin, detecting α-helix, β-sheet, and random coil content. The Glu6 → Val6 substitution alters hydrogen bonding and hydrophobic interactions, which can be tracked via CD signal changes under deoxygenated or polymerizing conditions. Structural insights from CD can be correlated with polymerization propensity, fiber rigidity, and the effect of small-molecule therapeutics [104,105].

X-ray Crystallography and Cryo-Electron Microscopy (Cryo-EM)

Atomic-resolution structures of HbS, its fibers, and drug complexes reveal the precise chemical environment of the Val6 hydrophobic pocket and heme groups. Crystallography allows identification of covalent and non-covalent drug-binding sites, while Cryo-EM captures fiber formation dynamics in near-native states. These techniques provide chemically grounded blueprints for rational design of polymerization inhibitors, allosteric modulators, and oxidative stress-targeting molecules [110].

Chemical Insight

Spectroscopic and structural data provide direct evidence of molecular interactions, linking chemical modifications to biophysical outcomes.

By integrating these techniques, chemists can rationally design, optimize, and evaluate therapeutics, ensuring targeted modulation of HbS polymerization, oxygen affinity, and redox chemistry.

6.2. Computational Modeling of HbS and Therapeutics

Computational chemistry provides atomic- and molecular-level insights into HbS polymerization, redox processes, and drug interactions, complementing experimental approaches. These methods are critical for rational therapeutic design and understanding chemical mechanisms [111].

Molecular Dynamics (MD) Simulations

MD simulations model the time-resolved motions of HbS molecules:

- **Nucleation and fiber elongation:** Simulations reveal how deoxy-HbS monomers self-assemble into oligomeric nuclei and fibers, highlighting Val6-mediated hydrophobic contacts as key nucleation sites.
- **Fiber stability:** MD trajectories provide quantitative information on hydrogen bonds, van der Waals contacts, and the persistence length of HbS fibers.
- **Drug interactions:** MD can assess how small molecules (e.g., Voxelotor, hydroxyurea derivatives) stabilize oxy-HbS, inhibit polymerization, or perturb fiber interfaces:

$$ce HbS_{deoxy} + Drug -> [MD simulation] HbS_{oxy} - Drug complex$$

Energetic analyses allow calculation of binding free energies (ΔG_bind), guiding structure-based optimization [112-115].

Docking Studies

Docking predicts binding affinities, orientations, and key interactions of small molecules with HbS.

Targets include:

- Val6 hydrophobic pockets – blocking fiber nucleation
- Allosteric sites on α-chain – stabilizing the R-state

Docking outputs are integrated with MD to assess dynamic stability and conformational flexibility, informing rational design of polymerization inhibitors [111–115].

Quantum Chemical Calculations

Evaluate electron density distributions in heme and adjacent residues.

Model redox reactions and Fenton-type chemistry:

$$ce Fe^{2+} - heme + H_2O_2 -> [QM] Fe^{3+} - heme + \bullet OH + OH^-$$

Quantum mechanical calculations provide insight into ROS generation, radical propagation, and thermodynamic feasibility, guiding the design of antioxidants and redox-targeting therapeutics [116–120].

6.3. Integration of Analytical and Computational Approaches

Combining spectroscopic, crystallographic, and computational techniques allows chemists to correlate chemical, structural, and functional data:

- **Structural-kinetic correlation:** Relate HbS fiber architecture (from X-ray or Cryo-EM) to polymerization rates (from MD and CD spectroscopy).
- **Redox mechanisms:** Quantum chemical calculations combined with UV-Vis spectroscopy reveal pathways of ROS generation and $Fe^{2+} \leftrightarrow Fe^{3+}$ transitions.
- **Drug efficacy prediction:** Docking and MD simulations predict binding modes and affinities prior to experimental validation.
- **Case study:** MD simulations and UV-Vis spectroscopy have validated Voxelotor-mediated stabilization of oxy-HbS, while docking studies guide optimization of small molecules that inhibit polymerization or allosterically modulate hemoglobin [121–125].

Chemical Insight: The integration of experimental and computational chemistry provides a rational, molecule-level framework for designing therapeutics, linking molecular interactions to biophysical properties and clinical outcomes.

7. KNOWLEDGE GAPS AND FUTURE DIRECTIONS

Despite decades of research, several chemical and molecular aspects of Sickle Cell Disease (SCD) remain incompletely understood, presenting opportunities for chemistry-driven therapeutic innovation.

7.1. Unresolved Molecular Mechanisms

- **Fiber nucleation kinetics:** While the role of Val6 hydrophobic interactions is established, the exact sequence of oligomer formation and lateral fiber aggregation at the atomic level is still unclear [126–130]. Advanced molecular dynamics simulations combined with time-resolved spectroscopy could resolve these transient intermediates.
- **Oxidative stress pathways:** Although ROS generation and detoxification reactions are known, the detailed chemical kinetics of Fenton-type reactions and heme auto-oxidation in sickled cells require further elucidation. Understanding these processes could enable targeted redox interventions [131–135].
- **Allosteric modulation by endogenous effectors:** Molecules like 2,3-bisphosphoglycerate (2,3-BPG) affect oxygen affinity, but their precise chemical influence on HbS polymerization dynamics is incompletely characterized [136–140].

7.2. Opportunities for Novel Chemical Therapeutics

- **Hydrophobic pocket inhibitors:** Small molecules designed to occupy the Val6 binding site remain underexplored. Rational design using computational docking and quantum chemical calculations could yield high-affinity polymerization inhibitors [141–145].
- **Redox-targeting compounds:** Synthetic antioxidants and enzyme mimetics (SOD/catalase analogs) could directly modulate ROS chemistry in sickled cells. Fine-tuning their reactivity, cellular permeability, and redox potential is a critical chemical challenge [146–150].

- **Allosteric modulators:** New chemical scaffolds that stabilize the R-state or modulate HbS oxygen affinity could complement existing therapies like Voxelotor. Structure-guided chemical design is essential for optimizing efficacy and specificity [151–155].

7.3. Integrating Experimental and Computational Chemistry

Future SCD research should integrate analytical chemistry, computational modeling, and chemical biology to:

- Map atomistic mechanisms of HbS polymerization and oxidative reactions.
- Design next-generation small molecules that interfere with polymerization or redox cascades.
- Validate chemical hypotheses with spectroscopy, crystallography, and in vitro/in vivo assays.

This chemist-centric approach ensures that molecular insights drive translational outcomes, bridging the gap from chemical mechanism to clinical intervention [156–160].

8. CONCLUSION

Sickle Cell Disease (SCD) exemplifies how a single molecular alteration , the Glu6 → Val6 substitution in hemoglobin, can cascade into complex chemical, biophysical, and physiological consequences. From a chemist's perspective, SCD is not merely a genetic disorder; it is fundamentally a chemical problem in which hydrophobic interactions, polymerization kinetics, redox reactions, and allosteric modulation dictate the pathophysiology.

This review underscores the centrality of chemical principles in understanding SCD. The molecular chemistry of HbS demonstrates how Val6 residues initiate fiber nucleation and elongation, while the biophysical dynamics of polymer formation integrate hydrophobic contacts, hydrogen bonding, and fiber rigidity, directly influencing red blood cell deformability and vaso-occlusion. Redox chemistry and oxidative stress pathways, including heme auto-oxidation, superoxide and hydroxyl radical generation, and glutathione-mediated detoxification, highlight the molecular basis of hemolysis and cellular damage. Chemical therapeutics, such as hydroxyurea, Voxelotor, and L-Glutamine, exemplify how targeted molecular interventions can modulate polymerization, oxygen affinity, and reactive oxygen species, translating chemical mechanisms into clinical benefits. Analytical and computational chemistry approaches further illuminate these processes, enabling rational drug design and predictive modeling of therapeutic efficacy.

Despite significant advances, critical knowledge gaps remain in fiber nucleation kinetics, detailed ROS reaction pathways, and allosteric regulation, offering opportunities for chemistry-driven innovation. By strategically integrating chemical structures, reaction mechanisms, and biochemical pathways, chemists can design next-generation therapeutics that directly target the molecular underpinnings of SCD, bridging fundamental chemistry, biophysics, and translational medicine.

Ultimately, viewing SCD through a chemist's lens not only deepens understanding of its molecular and biophysical basis but also provides a rational framework for precision interventions, fostering the development of molecularly informed therapies that transform patient outcomes.

Acknowledgement
Acknowledgments The authors appreciate the collaborative support of the Chemistry Collaborative Research Environment (CHEMCORE) for providing and enabling an academic network for interdisciplinary research discussions and technical guidance during manuscript preparation.

Author contributions
KSO conceptualized the study, drafted the manuscript, and supervised; OEF contributed to literature review and editing; AOD provided clinical insights and data support; all authors approved the final manuscript.

Declaration of Competing or Financial Interests
The authors declare that they have no competing financial or non-financial interests.

Funding
This research received no specific grant from any funding agency

Declaration of Generative AI and AI – Assisted technologies
The authors declare that no generative AI or AI-assisted technologies were used in the design, analysis, or preparation of this manuscript.

Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Availability of data
This review article did not generate new experimental data; all information was obtained from previously published studies, which are cited throughout the text.

Supplementary Information
No supplementary information is associated with this article.

Clinical trial number
Not applicable.

References

[1] Lettre G. Blocking HbS Polymerization in SCD. Cell. 2020 Mar 5;180(5):819. doi: 10.1016/j.cell.2020.01.019. PMID: 32142671.

[2] Suhail M. Biophysical chemistry behind sickle cell anemia and the mechanism of voxelotor action. Sci Rep. 2024 Jan 22;14(1):1861. doi: 10.1038/s41598-024-52476-8. PMID: 38253605; PMCID: PMC10803371.

[3] Nicola J Rutherford-Parker, Sean T Campbell, Jennifer M Colby, Zahra Shajani-Yi, Voxelotor Treatment Interferes With Quantitative and Qualitative Hemoglobin Variant Analysis in Multiple Sickle Cell Disease Genotypes, *American Journal of Clinical Pathology*, Volume 154, Issue 5, November 2020, Pages 627–634, https://doi.org/10.1093/ajcp/aqaa067

[4] Vichinsky E., et al. Voxelotor in SCD improves hemoglobin and reduces hemolysis: phase 3 results. *New Engl. J. Med.* 2019. https://doi.org/10.1056/NEJMoa1903212

[5] Steinberg MH, Sebastiani P. Genetic modifiers of sickle cell disease. American journal of hematology. 2012 Aug;87(8):795-803. https://doi.org/10.1002/ajh.23232

[6] Gopalsamy A, Aulabaugh AE, Barakat A, Beaumont KC, Cabral S, Canterbury DP, Casimiro-Garcia A, Chang JS, Chen MZ, Choi C, Dow RL. PF-07059013: a noncovalent modulator of hemoglobin for treatment of sickle cell disease. Journal of Medicinal Chemistry. 2020 Dec 24;64(1):326-42. https://doi.org/10.1021/acs.jmedchem.0c01518

[7] Wang Q, Zennadi R. The Role of RBC Oxidative Stress in Sickle Cell Disease: From the Molecular Basis to Pathologic Implications. Antioxidants (Basel). 2021 Oct 13;10(10):1608. doi: 10.3390/antiox10101608. PMID: 34679742; PMCID: PMC8533084.

[8] Nolfi-Donegan D, Pradhan-Sundd T, Pritchard KA Jr, Hillery CA. Redox Signaling in Sickle Cell Disease. Curr Opin Physiol. 2019 Jun;9:26-33. doi: 10.1016/j.cophys.2019.04.022. Epub 2019 May 2. PMID: 31240269; PMCID: PMC6592428.

[9] Alayash AI. Oxidative pathways in the sickle cell and beyond. Blood Cells Mol Dis. 2018 May;70:78-86. doi: 10.1016/j.bcmd.2017.05.009. Epub 2017 May 20. PMID: 28554826; PMCID: PMC5696113.

[10] Sundd P, Gladwin MT, Novelli EM. Pathophysiology of Sickle Cell Disease. Annu Rev Pathol. 2019 Jan 24;14:263-292. doi: 10.1146/annurev-pathmechdis-012418-012838. Epub 2018 Oct 17. PMID: 30332562; PMCID: PMC7053558.

[11] Eaton WA, Hofrichter J. Sickle cell hemoglobin polymerization. Adv Protein Chem. 1990;40:63-279. doi: 10.1016/s0065-3233(08)60287-9. PMID: 2195851.

[12] Vekilov PG. Sickle-cell haemoglobin polymerization: is it the primary pathogenic event of sickle-cell anaemia? Br J Haematol. 2007 Oct;139(2):173-84. doi: 10.1111/j.1365-2141.2007.06794.x. PMID: 17897293.

[13] Makhijani VB, Cokelet GR. In vivo polymerization of sickle-cell hemoglobin: a theoretical study. Blood Cells. 1994;20(1):169-83; discussion 184-90. PMID: 7994059.

[14] Hofrichter J. Kinetics of sickle hemoglobin polymerization. III. Nucleation rates determined from stochastic fluctuations in polymerization progress curves. J Mol Biol. 1986 Jun 5;189(3):553-71. doi: 10.1016/0022-2836(86)90324-4. PMID: 3783684.

[15] Breedlove SM. Hormonal control of the anatomical specificity of motoneuron-to-muscle innervation in rats. Science. 1985 Mar 15;227(4692):1357-9. doi: 10.1126/science.3975621. PMID: 3975621.

[16] Briehl RW, Nikolopoulou P. Kinetics of hemoglobin S polymerization and gelation under shear: I. Shape of the viscosity progress curve and dependence of delay time and reaction rate on shear rate and temperature. Blood. 1993 May 1;81(9):2420-8. PMID: 8481521.

[17] Nagamani Vunnam, Scott Hansen, Dillon C. Williams, MaryJane Olivia Been, Chih Hung Lo, Anil K. Pandey, Carolyn N. Paulson, John A. Rohde, David D. Thomas, Jonathan N. Sachs, and David K. Wood Biomacromolecules **2022** 23 (9), 3822-3830. DOI:10.1021/acs.biomac.2c00671

[18] Ferrone FA. Polymerization and sickle cell disease: a molecular view. Microcirculation. 2004 Mar;11(2):115-28. doi: 10.1080/10739680490278312. PMID: 15280087.

[19] Pagare PP, Rastegar A, Abdulmalik O, Omar AM, Zhang Y, Fleischman A, Safo MK. Modulating hemoglobin allostery for treatment of sickle cell disease: current progress and intellectual property. Expert Opin Ther Pat. 2022 Feb;32(2):115-130. doi: 10.1080/13543776.2022.1994945. Epub 2021 Nov 1. PMID: 34657559; PMCID: PMC8881396.

[20] Suhail M. Biophysical chemistry behind sickle cell anemia and the mechanism of voxelotor action. Sci Rep. 2024 Jan 22;14(1):1861. doi: 10.1038/s41598-024-52476-8. PMID: 38253605; PMCID: PMC10803371.

[21] Charache S, Terrin ML, Moore RD, Dover GJ, Barton FB, Eckert SV, McMahon RP, Bonds DR. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. N Engl J Med. 1995 May 18;332(20):1317-22. doi: 10.1056/NEJM199505183322001. PMID: 7715639.

[22] Niihara Y, Miller ST, Kanter J, Lanzkron S, Smith WR, Hsu LL, Gordeuk VR, Viswanathan K, Sarnaik S, Osunkwo I, Guillaume E, Sadanandan S, Sieger L, Lasky JL, Panosyan EH, Blake OA, New TN, Bellevue R, Tran LT, Razon RL, Stark CW, Neumayr LD, Vichinsky EP; Investigators of the Phase 3 Trial of l-Glutamine in Sickle Cell Disease. A Phase 3 Trial of l-Glutamine in Sickle Cell Disease. N Engl J Med. 2018 Jul 19;379(3):226-235. doi: 10.1056/NEJMoa1715971. PMID: 30021096.

[23] Taylor CM, Kasztan M, Sedaka R, Molina PA, Dunaway LS, Pollock JS, Pollock DM. Hydroxyurea improves nitric oxide bioavailability in humanized sickle cell mice. Am J Physiol Regul Integr Comp Physiol. 2021 May 1;320(5):R630-R640. doi: 10.1152/ajpregu.00205.2020. Epub 2021 Feb 24. PMID: 33624556; PMCID: PMC8163606.

[24] Gladwin MT, Schechter AN. Nitric oxide therapy in sickle cell disease. Semin Hematol. 2001 Oct;38(4):333-42. doi: 10.1016/s0037-1963(01)90027-7. PMID: 11605168.

[25] Mbadiko, C.M., Ngbolua, KtN., Bongo, G.N. *et al.* In vitro evaluation of curcumin's antisickling activity and in silico analysis of curcuminoids and their ADMET properties. *Discov. Chem.* **2**, 113 (2025). https://doi.org/10.1007/s44371-025-00171-6

[26] Nolfi-Donegan D, Pradhan-Sundd T, Pritchard KA Jr, Hillery CA. Redox Signaling in Sickle Cell Disease. Curr Opin Physiol. 2019 Jun;9:26-33. doi: 10.1016/j.cophys.2019.04.022. Epub 2019 May 2. PMID: 31240269; PMCID: PMC6592428.

[27] Strader, M.B., Jana, S., Meng, F. *et al.* Post-translational modification as a response to cellular stress induced by hemoglobin oxidation in sickle cell disease. *Sci Rep* **10**, 14218 (2020). https://doi.org/10.1038/s41598-020-71096-6

[28] Vona, R.; Sposi, N.M.; Mattia, L.; Gambardella, L.; Straface, E.; Pietraforte, D. Sickle Cell Disease: Role of Oxidative Stress and Antioxidant Therapy. *Antioxidants* **2021**, *10*, 296. https://doi.org/10.3390/antiox10020296

[29] Alayash AI. Oxidative pathways in the sickle cell and beyond. Blood Cells Mol Dis. 2018 May;70:78-86. doi: 10.1016/j.bcmd.2017.05.009. Epub 2017 May 20. PMID: 28554826; PMCID: PMC5696113.

[30] George A, Pushkaran S, Konstantinidis DG, Koochaki S, Malik P, Mohandas N, Zheng Y, Joiner CH, Kalfa TA. Erythrocyte NADPH oxidase activity modulated by Rac GTPases, PKC, and plasma cytokines contributes to oxidative stress in sickle cell disease. Blood. 2013 Mar 14;121(11):2099-107. doi: 10.1182/blood-2012-07-441188. Epub 2013 Jan 24. Erratum in: Blood. 2014 Mar 20;123(12):1972. PMID: 23349388; PMCID: PMC3596970.

[31] Dykes, G., Crepeau, R. & Edelstein, S. Three-dimensional reconstruction of the fibres of sickle cell haemoglobin. *Nature* **272**, 506–510 (1978). https://doi.org/10.1038/272506a0

[32] Magdoff-Fairchild B, Poillon WN, Li T, Bertles JF. Thermodynamic studies of polymerization of deoxygenated sickle cell hemoglobin. Proc Natl Acad Sci U S A. 1976 Apr;73(4):990-4. doi: 10.1073/pnas.73.4.990. PMID: 4799; PMCID: PMC430183.

[33] Sunshine HR, Hofrichter J, Eaton WA. Gelation of sickle cell hemoglobin in mixtures with normal adult and fetal hemoglobins. J Mol Biol. 1979 Oct 9;133(4):435-67. doi: 10.1016/0022-2836(79)90402-9. PMID: 94101.

[34] Ferrone FA, Hofrichter J, Eaton WA. Kinetics of sickle hemoglobin polymerization. II. A double nucleation mechanism. J Mol Biol. 1985 Jun 25;183(4):611-31. doi: 10.1016/0022-2836(85)90175-5. PMID: 4020873.

[35] Lewis MR, Gross LJ, Josephs R. Cryo-electron microscopy of deoxy-sickle hemoglobin fibers. Microsc Res Tech. 1994 Apr 1;27(5):459-67. doi: 10.1002/jemt.1070270512. PMID: 8018998.

[36] Padlan EA, Love WE. Refined crystal structure of deoxyhemoglobin S. II. Molecular interactions in the crystal. J Biol Chem. 1985 Jul 15;260(14):8280-91. PMID: 2409085.

[37] Harrington DJ, Adachi K, Royer WE Jr. The high resolution crystal structure of deoxyhemoglobin S. J Mol Biol. 1997 Sep 26;272(3):398-407. doi: 10.1006/jmbi.1997.1253. PMID: 9325099.

[38] Dykes G, Crepeau RH, Edelstein SJ. Three-dimensional reconstruction of the fibres of sickle cell haemoglobin. Nature. 1978 Apr 6;272(5653):506-10. doi: 10.1038/272506a0. PMID: 692655.

[39] Briehl RW, Ewert S. Effects of pH, 2,3-diphosphoglycerate and salts on gelation of sickle cell deoxyhemoglobin. J Mol Biol. 1973 Nov 5;80(3):445-58. doi: 10.1016/0022-2836(73)90415-4. PMID: 4762563.

[40] Poillon WN, Kim BC, Labotka RJ, Hicks CU, Kark JA. Antisickling effects of 2,3-diphosphoglycerate depletion. Blood. 1995 Jun 1;85(11):3289-96. PMID: 7756662.

[41] Hebbel RP, Morgan WT, Eaton JW, Hedlund BE. Accelerated autoxidation and heme loss due to instability of sickle hemoglobin. Proc Natl Acad Sci U S A. 1988 Jan;85(1):237-41. doi: 10.1073/pnas.85.1.237. PMID: 3422420; PMCID: PMC279519.

[42] Winterbourn CC. Oxidative reactions of hemoglobin. Methods Enzymol. 1990;186:265-72. doi: 10.1016/0076-6879(90)86118-f. PMID: 2172706.

[43] Queiroz RF, Lima ES. Oxidative stress in sickle cell disease. Rev Bras Hematol Hemoter. 2013;35(1):16-7. doi: 10.5581/1516-8484.20130008. PMID: 23580878; PMCID: PMC3621629.

[44] Kato GJ, McGowan V, Machado RF, Little JA, Taylor J 6th, Morris CR, Nichols JS, Wang X, Poljakovic M, Morris SM Jr, Gladwin MT. Lactate dehydrogenase as a biomarker of hemolysis-associated nitric oxide resistance, priapism, leg ulceration, pulmonary hypertension, and death in patients with sickle cell disease. Blood. 2006 Mar 15;107(6):2279-85. doi: 10.1182/blood-2005-06-2373. Epub 2005 Nov 15. PMID: 16291595; PMCID: PMC1895723.

[45] Reiter, C., Wang, X., Tanus-Santos, J. *et al.* Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease. *Nat Med* **8**, 1383–1389 (2002). https://doi.org/10.1038/nm1202-799

[46] Aslan M, Thornley-Brown D, Freeman BA. Reactive species in sickle cell disease. Ann N Y Acad Sci. 2000;899:375-91. doi: 10.1111/j.1749-6632.2000.tb06201.x. PMID: 10863554.

[47] Dong C, Chadwick RS, Schechter AN. Influence of sickle hemoglobin polymerization and membrane properties on deformability of sickle erythrocytes in the microcirculation. Biophys J. 1992 Sep;63(3):774-83. doi: 10.1016/S0006-3495(92)81655-7. PMID: 1420913; PMCID: PMC1262210.

[48] Conran N, Embury SH. Sickle cell vaso-occlusion: The dialectic between red cells and white cells. Exp Biol Med (Maywood). 2021 Jun;246(12):1458-1472. doi: 10.1177/15353702211005392. Epub 2021 Apr 1. PMID: 33794696; PMCID: PMC8243211.

[49] Eaton WA, Hofrichter J. Hemoglobin S gelation and sickle cell disease. Blood. 1987 Nov;70(5):1245-66. PMID: 3311198.

[50] Ho C, Willis BF, Shen TJ, Dazhen NT, Sun DP, Tam MF, Suzuka SM, Fabry ME, Nagel RL. Roles of alpha 114 and beta 87 amino acid residues in the polymerization of hemoglobin S: implications for gene therapy. J Mol Biol. 1996 Nov 1;263(3):475-85. doi: 10.1006/jmbi.1996.0590. PMID: 8918602.

[51] Briehl RW. Nucleation, fiber growth and melting, and domain formation and structure in sickle cell hemoglobin gels. J Mol Biol. 1995 Feb 3;245(5):710-23. doi: 10.1006/jmbi.1994.0057. PMID: 7844835.

[52] Ferrone FA, Rotter MA, Hofrichter J, Eaton WA.
Kinetics of sickle hemoglobin polymerization. IV. Temperature dependence of the delay time.
J Mol Biol. 1985;183(4):591–610.

[53] Mozzarelli A, Hofrichter J, Eaton WA. Delay time of hemoglobin S polymerization prevents most cells from sickling in vivo. Science. 1987 Jul 31;237(4814):500-6. doi: 10.1126/science.3603036. PMID: 3603036.

[54] Noguchi CT, Torchia DA, Schechter AN. Intracellular polymerization of sickle hemoglobin. Effects of cell heterogeneity. J Clin Invest. 1983 Sep;72(3):846-52. doi: 10.1172/JCI111055. PMID: 6886006; PMCID: PMC1129249.

[55] Adeleke OT, Olasinde YT, Folaranmi OE, Ayuba YL, Agelebe E, Rufai MM, Adeleke OV, Adeoye OE, Olabode AT, Ajala DE, Akingbola TS. A qualitative enquiry into lived experience and coping strategies of undergraduates with sickle cell disease in Nigeria. BMC Public Health. 2024 Dec 5;24(1):3388. doi: 10.1186/s12889-024-20927-6. PMID: 39639223; PMCID: PMC11622687.

[56] Eaton WA. Hemoglobin S polymerization and sickle cell disease: A retrospective on the occasion of the 70th anniversary of Pauling's Science paper. Am J Hematol. 2020 Feb;95(2):205-211. doi: 10.1002/ajh.25687. Epub 2019 Dec 31. PMID: 31763707; PMCID: PMC7003899.

[57] Uzunova VV, Pan W, Galkin O, Vekilov PG. Free heme and the polymerization of sickle cell hemoglobin. Biophys J. 2010 Sep 22;99(6):1976-85. doi: 10.1016/j.bpj.2010.07.024. PMID: 20858444; PMCID: PMC2941010.

[58] Noguchi CT, Torchia DA, Schechter AN. Determination of deoxyhemoglobin S polymer in sickle erythrocytes upon deoxygenation. Proc Natl Acad Sci U S A. 1980 Sep;77(9):5487-91. doi: 10.1073/pnas.77.9.5487. PMID: 6933568; PMCID: PMC350086.

[59] Turner MS, Briehl RW, Ferrone FA, Josephs R. Twisted protein aggregates and disease: the stability of sickle hemoglobin fibers. Phys Rev Lett. 2003 Mar 28;90(12):128103. doi: 10.1103/PhysRevLett.90.128103. Epub 2003 Mar 28. PMID: 12688906.

[60] Medkour T, Ferrone F, Galactéros F, Hannaert P. The double nucleation model for sickle cell haemoglobin polymerization: full integration and comparison with experimental data. Acta Biotheor. 2008 Jun;56(1-2):103-22. doi: 10.1007/s10441-008-9032-2. Epub 2008 Feb 5. PMID: 18247134.

[61] Dou Q, Ferrone FA. Simulated formation of polymer domains in sickle hemoglobin. Biophys J. 1993 Nov;65(5):2068-77. doi: 10.1016/S0006-3495(93)81237-2. PMID: 8298036; PMCID: PMC1225942.

[62] Bosede Oluwasayo A, Benjamin Olamide A, Alaba Olanewaju D, Olufemi Ebenezer F, Ibrahim Abubakar B, Ogheneovo Ifedayo O, Wilson Shina A, Omotayo Oladele A, Akinbowale Romance E, Adebayo Augustine A, Ajayi Adeleke I, Michael Olumide G. SERUM TRACE ELEMENTS PICTURE IN SICKLE CELL ANAEMIA: A COMPARATIVE STUDY OF HBSS AND HBAA INDIVIDUALS AT A TEACHING HOSPITAL IN SOUTHWEST NIGERIA. GPH-IJBMS [Internet]. 16May2025 [cited 18Feb.2026];8(04):01-9. Available from: https://www.gphjournal.org/index.php/bs/article/view/1912

[63] Carragher B, Bluemke DA, Gabriel B, Potel MJ, Josephs R. Structural analysis of polymers of sickle cell hemoglobin. I. Sickle hemoglobin fibers. J Mol Biol. 1988 Jan 20;199(2):315-31. doi: 10.1016/0022-2836(88)90316-6. PMID: 3351926.

[64] Ferrone FA, Hofrichter J, Eaton WA. Kinetics of sickle hemoglobin polymerization. I. Studies using temperature-jump and laser photolysis techniques. J Mol Biol. 1985 Jun 25;183(4):591-610. doi: 10.1016/0022-2836(85)90174-3. PMID: 4020872.

[65] Rice-Evans C, Omorphos SC, Baysal E. Sickle cell membranes and oxidative damage. Biochem J. 1986 Jul 1;237(1):265-9. doi: 10.1042/bj2370265. PMID: 3800879; PMCID: PMC1146974.

[66] Hebbel RP, Eaton JW, Balasingam M, Steinberg MH. Spontaneous oxygen radical generation by sickle erythrocytes. J Clin Invest. 1982 Dec;70(6):1253-9. doi: 10.1172/jci110724. PMID: 6294138; PMCID: PMC370342.

[67] Aslan M, Freeman BA. Oxidant-mediated impairment of nitric oxide signaling in sickle cell disease--mechanisms and consequences. Cell Mol Biol (Noisy-le-grand). 2004 Feb;50(1):95-105. PMID: 15040433.

[68] Kato GJ, Steinberg MH, Gladwin MT. Intravascular hemolysis and the pathophysiology of sickle cell disease. J Clin Invest. 2017 Mar 1;127(3):750-760. doi: 10.1172/JCI89741. Epub 2017 Mar 1. PMID: 28248201; PMCID: PMC5330745.

[69] Kato GJ, Gladwin MT, Steinberg MH. Deconstructing sickle cell disease: reappraisal of the role of hemolysis in the development of clinical subphenotypes. Blood Rev. 2007 Jan;21(1):37-47. doi: 10.1016/j.blre.2006.07.001. Epub 2006 Nov 7. PMID: 17084951; PMCID: PMC2048670.

[70] Kaul DK, Fabry ME, Nagel RL. Microvascular sites and characteristics of sickle cell adhesion to vascular endothelium in shear flow conditions: pathophysiological implications. Proc Natl Acad Sci U S A. 1989 May;86(9):3356-60. doi: 10.1073/pnas.86.9.3356. PMID: 2497465; PMCID: PMC287131.

[71] Mohandas N, Clark MR, Jacobs MS, Shohet SB. Analysis of factors regulating erythrocyte deformability. J Clin Invest. 1980 Sep;66(3):563-73. doi: 10.1172/JCI109888. PMID: 6156955; PMCID: PMC371685.

[72] Dong C, Chadwick RS, Schechter AN. Influence of sickle hemoglobin polymerization and membrane properties on deformability of sickle erythrocytes in the microcirculation. Biophys J. 1992 Sep;63(3):774-83. doi: 10.1016/S0006-3495(92)81655-7. PMID: 1420913; PMCID: PMC1262210.

[73] Joiner CH. Cation transport and volume regulation in sickle red blood cells. Am J Physiol. 1993 Feb;264(2 Pt 1):C251-70. doi: 10.1152/ajpcell.1993.264.2.C251. PMID: 8447360.

[74] Bookchin RM, Lew VL. Pathophysiology of sickle cell anemia. Hematol Oncol Clin North Am. 1996 Dec;10(6):1241-53. doi: 10.1016/s0889-8588(05)70397-x. PMID: 8956013.

[75] Gibson JS, Ellory JC. Membrane transport in sickle cell disease. Blood Cells Mol Dis. 2002 May-Jun;28(3):303-14. doi: 10.1006/bcmd.2002.0515. PMID: 12367577.

[76] Eaton WA. Hemoglobin S polymerization and sickle cell disease: A retrospective on the occasion of the 70th anniversary of Pauling's Science paper. Am J Hematol. 2020 Feb;95(2):205-211. doi: 10.1002/ajh.25687. Epub 2019 Dec 31. PMID: 31763707; PMCID: PMC7003899.

[77] Rotter MA, Kwong S, Briehl RW, Ferrone FA. Heterogeneous nucleation in sickle hemoglobin: experimental validation of a structural mechanism. Biophys J. 2005 Oct;89(4):2677-84. doi: 10.1529/biophysj.105.067785. Epub 2005 Jul 29. PMID: 16055526; PMCID: PMC1366768.

[78] Briehl RW, Mann ES. Hemoglobin S polymerization. Fiber lengths, rheology, and pathogenesis. Ann N Y Acad Sci. 1989;565:295-307. doi: 10.1111/j.1749-6632.1989.tb24177.x. PMID: 2672966.

[79] Dong A, Huang P, Caughey WS. Protein secondary structures in water from second-derivative amide I infrared spectra. Biochemistry. 1990 Apr 3;29(13):3303-8. doi: 10.1021/bi00465a022. PMID: 2159334.

[80] Eisenberger P, Shulman RG, Brown GS, Ogawa S. Structure-function relations in hemoglobin as determined by x-ray absorption spectroscopy. Proc Natl Acad Sci U S A. 1976 Feb;73(2):491-5. doi: 10.1073/pnas.73.2.491. PMID: 1061148; PMCID: PMC335935.

[81] Abdulmalik O, Safo MK, Chen Q, Yang J, Brugnara C, Ohene-Frempong K, Abraham DJ, Asakura T. 5-hydroxymethyl-2-furfural modifies intracellular sickle haemoglobin and inhibits sickling of red blood cells. Br J Haematol. 2005 Feb;128(4):552-61. doi: 10.1111/j.1365-2141.2004.05332.x. PMID: 15686467.

[82] Pagare PP, Ghatge MS, Chen Q, Musayev FN, Venitz J, Abdulmalik O, Zhang Y, Safo MK. Exploration of Structure-Activity Relationship of Aromatic Aldehydes Bearing Pyridinylmethoxy-Methyl Esters as Novel Antisickling Agents. J Med Chem. 2020 Dec 10;63(23):14724-14739. doi: 10.1021/acs.jmedchem.0c01287. Epub 2020 Nov 18. PMID: 33205981; PMCID: PMC7869023.

[83] Lal J, Maccarini M, Fouquet P, Ho NT, Ho C, Makowski L. Modulation of hemoglobin dynamics by an allosteric effector. Protein Sci. 2017 Mar;26(3):505-514. doi: 10.1002/pro.3099. Epub 2017 Feb 14. PMID: 27977887; PMCID: PMC5326564.

[84] Oksenberg D, Dufu K, Patel MP, Chuang C, Li Z, Xu Q, Silva-Garcia A, Zhou C, Hutchaleelaha A, Patskovska L, Patskovsky Y, Almo SC, Sinha U, Metcalf BW, Archer DR. GBT440 increases haemoglobin oxygen affinity, reduces sickling and prolongs RBC half-life in a murine model of sickle cell disease. Br J Haematol. 2016 Oct;175(1):141-53. doi: 10.1111/bjh.14214. Epub 2016 Jul 5. PMID: 27378309.

[85] Henry ER, Metaferia B, Li Q, Harper J, Best RB, Glass KE, Cellmer T, Dunkelberger EB, Conrey A, Thein SL, Bunn HF, Eaton WA. Treatment of sickle cell disease by increasing oxygen affinity of hemoglobin. Blood. 2021 Sep 30;138(13):1172-1181. doi: 10.1182/blood.2021012070. PMID: 34197597; PMCID: PMC8570057.

[86] Chonat S, Fields E, Baratz H, Watt A, Pochron M, Dixon S, Tonda M, Brown C, Archer D. Voxelotor improves red blood cell functionality in children with sickle cell anaemia: An ancillary study of the HOPE-KIDS 1 trial. EJHaem. 2024 Jan 30;5(1):125-130. doi: 10.1002/jha2.831. PMID: 38406531; PMCID: PMC10887232.

[87] Prabhakaran M, Johnson ME. Molecular dynamics of sickle and normal hemoglobins. Biopolymers. 1993 May;33(5):735-42. doi: 10.1002/bip.360330503. PMID: 8343575.

[88] Li H, Lykotrafitis G. A coarse-grain molecular dynamics model for sickle hemoglobin fibers. J Mech Behav Biomed Mater. 2011 Feb;4(2):162-73. doi: 10.1016/j.jmbbm.2010.11.002. Epub 2010 Nov 10. PMID: 21262494.

[89] Santiago PS, Moura F, Moreira LM, Domingues MM, Santos NC, Tabak M. Dynamic light scattering and optical absorption spectroscopy study of pH and temperature stabilities of the extracellular hemoglobin of Glossoscolex paulistus. Biophys J. 2008 Mar 15;94(6):2228-40. doi: 10.1529/biophysj.107.116780. Epub 2007 Dec 7. PMID: 18065453; PMCID: PMC2257920.

[90] Zhou HX, Ferrone FA. Theoretical description of the spatial dependence of sickle hemoglobin polymerization. Biophys J. 1990 Sep;58(3):695-703. doi: 10.1016/S0006-3495(90)82412-7. PMID: 2207259; PMCID: PMC1281010.

[91] Nantasenamat C, Prachayasittikul V, Bulow L. Molecular modeling of the human hemoglobin-haptoglobin complex sheds light on the protective mechanisms of haptoglobin. PLoS One. 2013 Apr 26;8(4):e62996. doi: 10.1371/journal.pone.0062996. PMID: 23638175; PMCID: PMC3637213.

[92] Ip CY, Asakura T, Adachi K. Polymerization of binary mixtures of hemoglobin S and carbamylated hemoglobin S. J Biol Chem. 1984 Jan 10;259(1):244-8. PMID: 6706933.

[93] Kaul DK, Fabry ME. In vivo studies of sickle red blood cells. Microcirculation. 2004 Mar;11(2):153-65. PMID: 15280089.

[94] Morris CR. Mechanisms of vasculopathy in sickle cell disease and thalassemia. Hematology Am Soc Hematol Educ Program. 2008:177-85. doi: 10.1182/asheducation-2008.1.177. PMID: 19074078.

[95] Gbotosho OT, Kapetanaki MG, Kato GJ. The Worst Things in Life are Free: The Role of Free Heme in Sickle Cell Disease. Front Immunol. 2021 Jan 27;11:561917. doi: 10.3389/fimmu.2020.561917. PMID: 33584641; PMCID: PMC7873693.

[96] Ghosh S, Adisa OA, Chappa P, Tan F, Jackson KA, Archer DR, Ofori-Acquah SF. Extracellular hemin crisis triggers acute chest syndrome in sickle mice. J Clin Invest. 2013 Nov;123(11):4809-20. doi: 10.1172/JCI64578. PMID: 24084741; PMCID: PMC3809772.

[97] Mollan TL, Alayash AI. Redox reactions of hemoglobin: mechanisms of toxicity and control. Antioxid Redox Signal. 2013 Jun 10;18(17):2251-3. doi: 10.1089/ars.2013.5195. Epub 2013 Feb 28. PMID: 23330885; PMCID: PMC3638555.

[98] Mack AK, Kato GJ. Sickle cell disease and nitric oxide: a paradigm shift? Int J Biochem Cell Biol. 2006;38(8):1237-43. doi: 10.1016/j.biocel.2006.01.010. Epub 2006 Feb 17. PMID: 16517208; PMCID: PMC2199240.

[99] Rees DC, Williams TN, Gladwin MT. Sickle-cell disease. Lancet. 2010 Dec 11;376(9757):2018-31. doi: 10.1016/S0140-6736(10)61029-X. Epub 2010 Dec 3. PMID: 21131035.

[100] Steinberg MH. Pathophysiology of sickle cell disease. Baillieres Clin Haematol. 1998 Mar;11(1):163-84. doi: 10.1016/s0950-3536(98)80074-7. PMID: 10872477.

[101] Antonini, E. and Brunori, M. (1971) Hemoglobin and Myoglobin in the Reactions with Ligands. In: Neuberger, A. and Tatum, E.L., Eds., North-Holland Research Monographs. Frontiers of Biology, Vol. 21, North-Holland Publishing Company, Amsterdam and London, 276.

[102] Schechter AN. Hemoglobin research and the origins of molecular medicine. Blood. 2008 Nov 15;112(10):3927-38. doi: 10.1182/blood-2008-04-078188. PMID: 18988877; PMCID: PMC2581994.

[103] Perutz MF. Stereochemistry of cooperative effects in haemoglobin. Nature. 1970 Nov 21;228(5273):726-39. doi: 10.1038/228726a0. PMID: 5528785.

[104] Kelly SM, Jess TJ, Price NC. How to study proteins by circular dichroism. Biochim Biophys Acta. 2005 Aug 10;1751(2):119-39. doi: 10.1016/j.bbapap.2005.06.005. PMID: 16027053.

[105] Greenfield NJ. Using circular dichroism spectra to estimate protein secondary structure. Nat Protoc. 2006;1(6):2876-90. doi: 10.1038/nprot.2006.202. PMID: 17406547; PMCID: PMC2728378.

[106] Henry ER, Cellmer T, Dunkelberger EB, Metaferia B, Hofrichter J, Li Q, Ostrowski D, Ghirlando R, Louis JM, Moutereau S, Galactéros F, Thein SL, Bartolucci P, Eaton WA. Allosteric control of hemoglobin S fiber formation by oxygen and its relation to the pathophysiology of sickle cell disease. Proc Natl Acad Sci U S A. 2020 Jun 30;117(26):15018-15027. doi: 10.1073/pnas.1922004117. Epub 2020 Jun 11. PMID: 32527859; PMCID: PMC7334536.

[107] Acharya AS, Khandke L. Selective amidation of carboxyl groups of the intermolecular contact regions of hemoglobin S: structural aspects. J Protein Chem. 1989 Apr;8(2):231-7. doi: 10.1007/BF01024946. PMID: 2736042.

[108] Hofrichter J, Hendricker DG, Eaton WA. Structure of hemoglobin S fibers: optical determination of the molecular orientation in sickled erythrocytes. Proc Natl Acad Sci U S A. 1973 Dec;70(12):3604-8. doi: 10.1073/pnas.70.12.3604. PMID: 4519649; PMCID: PMC427289.

[109] Yuan Y, Tam MF, Simplaceanu V, Ho C. New look at hemoglobin allostery. Chem Rev. 2015 Feb 25;115(4):1702-24. doi: 10.1021/cr500495x. Epub 2015 Jan 21. PMID: 25607981; PMCID: PMC4507747.

[110] Ahmed MH, Ghatge MS, Safo MK. Hemoglobin: Structure, Function and Allostery. Subcell Biochem. 2020;94:345-382. doi: 10.1007/978-3-030-41769-7_14. PMID: 32189307; PMCID: PMC7370311.

[111] Ma YW, Wang GF, Chen HY, Tsai MY. Exploring Abeta42 monomer diffusion dynamics on fibril surfaces through molecular simulations. Protein Sci. 2025 Jun;34(6):e70131. doi: 10.1002/pro.70131. PMID: 40371804; PMCID: PMC12079388.

[112] Galamba N, Pipolo S. On the Binding Free Energy and Molecular Origin of Sickle Cell Hemoglobin Aggregation. J Phys Chem B. 2018 Aug 2;122(30):7475-7483. doi: 10.1021/acs.jpcb.8b03708. Epub 2018 Jul 20. PMID: 29995412.

[113] Dror RO, Dirks RM, Grossman JP, Xu H, Shaw DE. Biomolecular simulation: a computational microscope for molecular biology. Annu Rev Biophys. 2012;41:429-52. doi: 10.1146/annurev-biophys-042910-155245. PMID: 22577825.

[114] Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS, Olson AJ. AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J Comput Chem. 2009 Dec;30(16):2785-91. doi: 10.1002/jcc.21256. PMID: 19399780; PMCID: PMC2760638.

[115] Meng XY, Zhang HX, Mezei M, Cui M. Molecular docking: a powerful approach for structure-based drug discovery. Curr Comput Aided Drug Des. 2011 Jun;7(2):146-57. doi: 10.2174/157340911795677602. PMID: 21534921; PMCID: PMC3151162.

[116] Singh P, Kumar V, Lee KW, Hong JC. Discovery of Novel Allosteric SHP2 Inhibitor Using Pharmacophore-Based Virtual Screening, Molecular Docking, Molecular Dynamics Simulation, and Principal Component Analysis. Pharmaceuticals (Basel). 2024 Jul 12;17(7):935. doi: 10.3390/ph17070935. PMID: 39065785; PMCID: PMC11280062.

[117] Poulos TL. Heme enzyme structure and function. Chem Rev. 2014 Apr 9;114(7):3919-62. doi: 10.1021/cr400415k. Epub 2014 Jan 8. PMID: 24400737; PMCID: PMC3981943.

[118] Birben E, Sahiner UM, Sackesen C, Erzurum S, Kalayci O. Oxidative stress and antioxidant defense. World Allergy Organ J. 2012 Jan;5(1):9-19. doi: 10.1097/WOX.0b013e3182439613. Epub 2012 Jan 13. PMID: 23268465; PMCID: PMC3488923.

[119] Guallar V, Wallrapp FH. QM/MM methods: looking inside heme proteins biochemistry. Biophys Chem. 2010 Jun;149(1-2):1-11. doi: 10.1016/j.bpc.2010.03.010. Epub 2010 Mar 20. PMID: 20400222.

[120] Case DA, Cheatham TE 3rd, Darden T, Gohlke H, Luo R, Merz KM Jr, Onufriev A, Simmerling C, Wang B, Woods RJ. The Amber biomolecular simulation programs. J Comput Chem. 2005 Dec;26(16):1668-88. doi: 10.1002/jcc.20290. PMID: 16200636; PMCID: PMC1989667.

[121] Ferrone FA. The delay time in sickle cell disease after 40 years: A paradigm assessed. Am J Hematol. 2015 May;90(5):438-45. doi: 10.1002/ajh.23958. Epub 2015 Feb 25. PMID: 25645011.

[122] Makhijani VB, Cokelet GR, Clark A Jr. Dynamics of oxygen unloading from sickle erythrocytes. Biophys J. 1990 Oct;58(4):1025-52.
doi: 10.1016/S0006-3495(90)82446-2. PMID: 2248988; PMCID: PMC1281047.

[123] Di Caprio G, Schonbrun E, Gonçalves BP, Valdez JM, Wood DK, Higgins JM. High-throughput assessment of hemoglobin polymer in single red blood cells from sickle cell patients under controlled oxygen tension. Proc Natl Acad Sci U S A. 2019 Dec 10;116(50):25236-25242. doi: 10.1073/pnas.1914056116. Epub 2019 Nov 25. PMID: 31767751; PMCID: PMC6911208.

[124] Henry ER, Cellmer T, Dunkelberger EB, Metaferia B, Hofrichter J, Li Q, Ostrowski D, Ghirlando R, Louis JM, Moutereau S, Galactéros F, Thein SL, Bartolucci P, Eaton WA. Allosteric control of hemoglobin S fiber formation by oxygen and its relation to the pathophysiology of sickle cell disease. Proc Natl Acad Sci U S A. 2020 Jun 30;117(26):15018-15027. doi: 10.1073/pnas.1922004117. Epub 2020 Jun 11. PMID: 32527859; PMCID: PMC7334536.

[125] Eaton WA. Impact of hemoglobin biophysical studies on molecular pathogenesis and drug therapy for sickle cell disease. Mol Aspects Med. 2022 Apr;84:100971. doi: 10.1016/j.mam.2021.100971. Epub 2021 Jul 14. PMID: 34274158; PMCID: PMC8758802.

[126] Cao Z, Ferrone FA. Homogeneous nucleation in sickle hemoglobin: stochastic measurements with a parallel method. Biophys J. 1997 Jan;72(1):343-52. doi: 10.1016/S0006-3495(97)78673-9. PMID: 8994619; PMCID: PMC1184323.

[127] Kaperonis AA, Handley DA, Chien S. Fibers, crystals, and other forms of HbS polymers in deoxygenated sickle erythrocytes. Am J Hematol. 1986 Mar;21(3):269-75. doi: 10.1002/ajh.2830210306. PMID: 3946409.

[128] Minton AP. A thermodynamic model for gelation of sickle-cell hemoglobin. J Mol Biol. 1974 Feb 5;82(4):483-98. doi: 10.1016/0022-2836(74)90243-5. PMID: 4817792.

[129] Cao Z, Liao D, Mirchev R, Martin de Llano JJ, Himanen JP, Manning JM, Ferrone FA. Nucleation and polymerization of sickle hemoglobin with Leu beta 88 substituted by Ala. J Mol Biol. 1997 Feb 7;265(5):580-9. doi: 10.1006/jmbi.1996.0749. PMID: 9048950.

[130] PAULING L, ITANO HA, et al. Sickle cell anemia a molecular disease. Science. 1949 Nov 25;110(2865):543-8. doi: 10.1126/science.110.2865.543. PMID: 15395398.

[131] Lubin, B., Kuypers, F., Vichinsky, E., Chiu, D. (1990). The Role of Oxidation in Diseases of the Human Erythrocyte. In: Pomerance, H.H., Bercu, B.B. (eds) Topics in Pediatrics. Springer, New York, NY. https://doi.org/10.1007/978-1-4612-3230-8_5

[132] Nur E, Biemond BJ, Otten HM, Brandjes DP, Schnog JJ; CURAMA Study Group. Oxidative stress in sickle cell disease; pathophysiology and potential implications for disease management. Am J Hematol. 2011 Jun;86(6):484-9. doi: 10.1002/ajh.22012. Epub 2011 May 4. PMID: 21544855.

[133] Pham PT, Pham PC, Wilkinson AH, Lew SQ. Renal abnormalities in sickle cell disease. Kidney Int. 2000 Jan;57(1):1-8. doi: 10.1046/j.1523-1755.2000.00806.x. PMID: 10620181.

[134] Schaer, C., Deuel, J., Bittermann, A. *et al.* Mechanisms of haptoglobin protection against hemoglobin peroxidation triggered endothelial damage. *Cell Death Differ* **20**, 1569–1579 (2013). https://doi.org/10.1038/cdd.2013.113

[135] Helms C, Kim-Shapiro DB. Hemoglobin-mediated nitric oxide signaling. Free Radic Biol Med. 2013 Aug;61:464-72. doi: 10.1016/j.freeradbiomed.2013.04.028. Epub 2013 Apr 26. PMID: 23624304; PMCID: PMC3849136.

[136] Bunn HF, Briehl RW. The interaction of 2,3-diphosphoglycerate with various human hemoglobins. J Clin Invest. 1970 Jun;49(6):1088-95. doi: 10.1172/JCI106324. PMID: 5422014; PMCID: PMC322576.

[137] Bunn HF. Differences in the interaction of 2,3-diphosphoglycerate with certain mammalian hemoglobins. Science. 1971 Jun 4;172(3987):1049-50. doi: 10.1126/science.172.3987.1049. PMID: 5573955.

[138] Perutz MF. Structure and mechanism of haemoglobin. Br Med Bull. 1976 Sep;32(3):195-208. doi: 10.1093/oxfordjournals.bmb.a071363. PMID: 788828.

[139] Eaton WA, Hofrichter J, Ross PD. Editorial: Delay time of gelation: a possible determinant of clinical severity in sickle cell disease. Blood. 1976 Apr;47(4):621-7. PMID: 1260125.

[140] Salhany JM, Eliot RS, Mizukami H. The effects of 2,3-diphosphoglycerate on the kinetics of deoxygenation of human hemoglobin. Biochem Biophys Res Commun. 1970;39(6):1052-7. doi: 10.1016/0006-291x(70)90665-0. PMID: 5513245.

[141] Oder E, Safo MK, Abdulmalik O, Kato GJ. New developments in anti-sickling agents: can drugs directly prevent the polymerization of sickle haemoglobin in vivo? Br J Haematol. 2016 Oct;175(1):24-30. doi: 10.1111/bjh.14264. Epub 2016 Sep 8. PMID: 27605087; PMCID: PMC5035193.

[142] Nakagawa A, Lui FE, Wassaf D, Yefidoff-Freedman R, Casalena D, Palmer MA, Meadows J, Mozzarelli A, Ronda L, Abdulmalik O, Bloch KD, Safo MK, Zapol WM. Identification of a small molecule that increases hemoglobin oxygen affinity and reduces SS erythrocyte sickling. ACS Chem Biol. 2014 Oct 17;9(10):2318-25.
doi: 10.1021/cb500230b. Epub 2014 Aug 11. PMID: 25061917; PMCID: PMC4205001.

[143] Alhashimi RT, Ghatge MS, Donkor AK, Deshpande TM, Anabaraonye N, Alramadhani D, Danso-Danquah R, Huang B, Zhang Y, Musayev FN, Abdulmalik O, Safo MK. Design, Synthesis, and Antisickling Investigation of a Nitric Oxide-Releasing Prodrug of 5HMF for the Treatment of Sickle Cell Disease. Biomolecules. 2022 May 12;12(5):696. doi: 10.3390/biom12050696. PMID: 35625623; PMCID: PMC9138457.

[144] Scannon PJ. Molecular modifications of hemoglobin. Crit Care Med. 1982 Apr;10(4):261-5. doi: 10.1097/00003246-198204000-00005. PMID: 6802571.

[145] Torres LS, Asada N, Weiss MJ, Trumpp A, Suda T, Scadden DT, Ito K. Recent advances in "sickle and niche" research - Tribute to Dr. Paul S Frenette. Stem Cell Reports. 2022 Jul 12;17(7):1509-1535. doi: 10.1016/j.stemcr.2022.06.004. PMID: 35830837; PMCID: PMC9287685.

[146] Batinić-Haberle I, Rebouças JS, Spasojević I. Superoxide dismutase mimics: chemistry, pharmacology, and therapeutic potential. Antioxid Redox Signal. 2010 Sep 15;13(6):877-918. doi: 10.1089/ars.2009.2876. PMID: 20095865; PMCID: PMC2935339.

[147] Day BJ. Catalase and glutathione peroxidase mimics. Biochem Pharmacol. 2009 Feb 1;77(3):285-96. doi: 10.1016/j.bcp.2008.09.029. Epub 2008 Oct 1. PMID: 18948086; PMCID: PMC2657365.

[148] Alayash AI. Hemoglobin Oxidation Reactions in Stored Blood. Antioxidants (Basel). 2022 Apr 8;11(4):747. doi: 10.3390/antiox11040747. PMID: 35453432; PMCID: PMC9027219.

[149] Belcher JD, Mahaseth H, Welch TE, Otterbein LE, Hebbel RP, Vercellotti GM. Heme oxygenase-1 is a modulator of inflammation and vaso-occlusion in transgenic sickle mice. J Clin Invest. 2006 Mar;116(3):808-16. doi: 10.1172/JCI26857. Epub 2006 Feb 16. PMID: 16485041; PMCID: PMC1366501.

[150] Alayash AI. Oxidative pathways in the sickle cell and beyond. Blood Cells Mol Dis. 2018 May;70:78-86. doi: 10.1016/j.bcmd.2017.05.009. Epub 2017 May 20. PMID: 28554826; PMCID: PMC5696113.

[151] Vichinsky E, Hoppe CC, Ataga KI, Ware RE, Nduba V, El-Beshlawy A, Hassab H, Achebe MM, Alkindi S, Brown RC, Diuguid DL, Telfer P, Tsitsikas DA, Elghandour A, Gordeuk VR, Kanter J, Abboud MR, Lehrer-Graiwer J, Tonda M, Intondi A, Tong B, Howard J; HOPE Trial Investigators. A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease. N Engl J Med. 2019 Aug 8;381(6):509-519. doi: 10.1056/NEJMoa1903212. Epub 2019 Jun 14. PMID: 31199090.

[152] Randad RS, Mahran MA, Mehanna AS, Abraham DJ. Allosteric modifiers of hemoglobin. 1. Design, synthesis, testing, and structure-allosteric activity relationship of novel hemoglobin oxygen affinity decreasing agents. J Med Chem. 1991 Feb;34(2):752-7. doi: 10.1021/jm00106a041. PMID: 1995897.

[153] Hyde RM, Livingstone DJ, Patterson RA, Batchelor JF, King WR. Modification of the haemoglobin oxygen dissociation curve in whole blood by a compound with dual action. Lancet. 1984 Jul 7;2(8393):15-6. doi: 10.1016/s0140-6736(84)92000-2. PMID: 6145935.

[154] Ferrone FA. The polymerization of sickle hemoglobin in solutions and cells. Experientia. 1993 Feb 15;49(2):110-7. doi: 10.1007/BF01989414. PMID: 8440349.

[155] Eaton WA, Bunn HF. Treating sickle cell disease by targeting HbS polymerization. Blood. 2017 May 18;129(20):2719-2726. doi: 10.1182/blood-2017-02-765891. Epub 2017 Apr 6. PMID: 28385699; PMCID: PMC5437829.

[156] Kato GJ, Piel FB, Reid CD, Gaston MH, Ohene-Frempong K, Krishnamurti L, Smith WR, Panepinto JA, Weatherall DJ, Costa FF, Vichinsky EP. Sickle cell disease. Nat Rev Dis Primers. 2018 Mar 15;4:18010. doi: 10.1038/nrdp.2018.10. PMID: 29542687.

[157] Ware RE, de Montalembert M, Tshilolo L, Abboud MR. Sickle cell disease. Lancet. 2017 Jul 15;390(10091):311-323. doi: 10.1016/S0140-6736(17)30193-9. Epub 2017 Feb 1. PMID: 28159390.

[158] Ataga KI, Kutlar A, Kanter J, Liles D, Cancado R, Friedrisch J, Guthrie TH, Knight-Madden J, Alvarez OA, Gordeuk VR, Gualandro S, Colella MP, Smith WR, Rollins SA, Stocker JW, Rother RP. Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease. N Engl J Med. 2017 Feb 2;376(5):429-439. doi: 10.1056/NEJMoa1611770. Epub 2016 Dec 3. PMID: 27959701; PMCID: PMC5481200.

[159] Niihara Y, Miller ST, Kanter J, Lanzkron S, Smith WR, Hsu LL, Gordeuk VR, Viswanathan K, Sarnaik S, Osunkwo I, Guillaume E, Sadanandan S, Sieger L, Lasky JL, Panosyan EH, Blake OA, New TN, Bellevue R, Tran LT, Razon RL, Stark CW, Neumayr LD, Vichinsky EP; Investigators of the Phase 3 Trial of l-Glutamine in Sickle Cell Disease. A Phase 3 Trial of l-Glutamine in Sickle Cell Disease. N Engl J Med. 2018 Jul 19;379(3):226-235. doi: 10.1056/NEJMoa1715971. PMID: 30021096.

[160] Darlison MW, Modell B. Sickle-cell disorders: limits of descriptive epidemiology. Lancet. 2013 Jan 12;381(9861):98-9. doi: 10.1016/S0140-6736(12)61817-0. Epub 2012 Oct 25. PMID: 23103088.